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ABSTRACT 
 
Aluminum is a known contaminant of parenteral nutrition (PN) solutions and 
it has been suspected to play a role in the development of parenteral nutrition 
associated cholestasis (PNAC).  The primary purpose of my research was to 
monitor the relationship between serum aluminum level and the development of 
PNAC in the infants with gastrointestinal failure who required PN therapy.  The 
secondary purpose was to develop a neonatal piglet model to compare different 
doses of aluminum or PN therapy with known aluminum level was associated with 
the development of PNAC. 
Sixteen infants with gastrointestinal pathology were enrolled in the study.  
Serum aluminum and bilirubin (direct and indirect) concentrations were determined 
on day 0, 7, 14, and 21 of PN therapy.  Five of sixteen (31.3%) infants developed 
PNAC by day 21.  Serum aluminum levels in infants receiving PN peaked at day 7 
of therapy and declined thereafter.  There was no direct correlation between serum 
direct bilirubin and serum aluminum levels. 
Twenty-four piglets, 2 to 4 days old, were placed into four groups: Control 
group (n=5); Low Al (aluminum) group (n=7), intravenous (iv) injection with 
aluminum dose at 20 μg·kg-1·day-1; High Al (aluminum) group (n=6), iv with 
aluminum dose at 1500 μg·kg-1·day-1; PN (parenteral nutrition) group (n=6), PN 
solutions with a mean aluminum intake at 37.8±14.3 μg·kg-1·day-1.  The experiment 
period was 21 days.  Serum bilirubin was significantly (p<0.05) elevated in the 
High Al and PN groups.  Liver aluminum concentration was significantly (p<0.05) 
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elevated in all the experimental groups and the relationship was dose dependant.  
Serum, and urine concentrations of aluminum were significantly (p<0.05) elevated in 
High Al but not the Low Al and PN groups.  Serum aluminum concentration was 
not correlated with serum total bilirubin levels. 
Cholestasis developed by 21 days in five infants and in the piglets of two 
experimental groups (the High Al group and the PN group).  High dose injection of 
aluminum may play a role in the development of PNAC in the neonatal piglets.  
The impact of aluminum may depend on the amount of pareternal aluminum intake 
and the presence of other potential factors such as lack of enternal feeding and 
individual physiological abilities. 
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1. INTRODUCTION 
1.1 Rationale 
Parenternal nutrition (PN) is a vital tool in the supportive care of premature 
and critically ill infants.  Cholestasis is a form of liver injury defined by a decrease 
or absence of bile flow into the duodenum (Erlinger, 1999).  It is one of the most 
common complications of PN, especially in infants.  The incidence of parenteral 
nutrition associated cholestasis (PNAC) was reported from 7.4% to 84% depending 
on birth weight, gestational age, as well as gastrointestional surgery, absence of oral 
intake, and diagnosis standards (Beath et al., 1996; Teitelbaum et al., 1997; Moss et 
al., 1999; Kubota et al., 2000).  The disease can progress from mild cholestatic liver 
disease to cirrhosis and hepatic failure (Shattuck and Klein, 2000).  PNAC has been 
shown to occur within two weeks of initiation of PN (Aynsley-Green, 1983).  The 
diagnosis of PNAC is usually made with the findings of increased serum alkaline 
phosphatase, direct bilirubin, and the exclusion of other causes of neonatal 
cholestasis (Gremse and Balistreri, 1989; Btaiche and Khalidi, 2002).  The 
pathogenesis of PNAC is still unclear.  Research data show that many factors 
including prematurity, low birth weight, lack of enteral feeding, sepsis, and toxicity 
of PN solutions have been implicated as possible contributing factors (Ginn-Pease et 
al., 1985; Beath et al., 1996; Shattuck and Klein, 2000).  However, the contributions 
of these factors in the development of PNAC are speculative.  
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One constituent of PN solutions that has been implicated in PNAC is the 
contaminant aluminum.  Aluminum is one of the most abundant elements of the 
earth.  Aluminum can be ingested as a contaminant of medications, food and water.  
Less than 1% of ingested aluminum is absorbed through the gastrointestinal tract 
(Moreno et al., 1994).  Once absorbed, it is bound to the plasma protein transferrin 
and, to a lesser extent, albumin, then transported via the portal vein to the liver 
(Trapp, 1983; Bertholf et al., 1984).  Aluminum has been found to deposit in 
lysosomes of macrophages and in lipofuscin granules of hepatocytes.  Moreover, 
this aluminum accumulation was associated with severe ultrastructure lesions in 
these cells (Galle et al., 1987).  Aluminum has been implicated in the progress of 
several diseases, including cholestasis, osteopenic bone disease, microcytic anemia, 
Alzheimer’s disease, as well as encephalopathy (Klein et al., 1995; Koo et al., 1992; 
Recknagel et al., 1994).  Absorbed aluminum is primarily excreted via the kidneys. 
(Greger and Sutherland, 1997).  
Aluminum contamination of PN solutions has been known for more than two 
decades (Klein, 2003).  Small volume additives to PN, such as heparin, calcium, 
phosphate salts, and blood products like albumin are contaminated with aluminum 
(ASCN/ASPEN, 1991; Popinska et al., 1999).  Research on aluminum in neonatal 
parenteral nutrition solutions showed that the level of contamination ranged from 
4.16 to 7.26 µmol·L-1 representing an average intake of 16.7 µg·kg-1·day-1 (Moreno 
et al., 1994).  This level significantly exceeds the 2 µg·kg-1·day-1 safe level that is 
recommended for the adult by the American Society of Clinical Nutrition / American 
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Society of Enteral Nutrition and Parenteral Nutrition joint commission 
(ASCN/ASPEN, 1991).  
A few studies have investigated the role of aluminum in PNAC.  Klein et al. 
(1984) examined hepatic aluminum accumulation in five children who developed 
PNAC while on long-term parenteral nutrition.  All five demonstrated moderate to 
severe cholestatic changes in the liver.  The hepatic aluminum concentrations were 
elevated, ranging from 5 to 27 times more than normal.  In addition, significantly 
increased serum and urine aluminum levels were also found in these children.  
They concluded that aluminum loading might contribute to the pathogenesis of 
parenteral nutrition induced hepatocellular dysfunction (Klein et al., 1984).  In a 
prospective study of 35 newborn infants, PN solutions accounted for 88.7% of the 
total aluminum intake (Moreno et al., 1994).  Serum and urine aluminum levels in 
infants who required PN were significantly higher compared to a control group of 
formula fed infants.  The PN group had greater hepatic tissue aluminum level than 
the controls.  Klein et al. (1987) also used a piglet model to study the association 
between parenteral aluminum and PNAC.  Increased serum bile acids and alkaline 
phosphatase levels were shown in the aluminum loaded piglets, suggesting that 
cholestasis had developed (Klein et al., 1987).  The same research group also 
explored the relationships to dosage and duration of exposure in aluminum 
associated hepatobiliary dysfunction in rats (Klein et al., 1988).  Further there was 
another report in which the intraperitoneal administration of aluminum produced 
portal inflammation in rats and a dose related elevation in the levels of serum bile 
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acids was found (Dermican et al., 1998).  Both results suggested that aluminum 
exposure in rats associated with elevated serum bile acid concentration and 
diminished bile flow may play a role in PNAC (Klein et al., 1988; Dermican et al., 
1998; Gonzalez et al., 2004).  
Although previous studies suggested an association between aluminum and 
PNAC, the role of aluminum in PNAC is still unclear.  The sample sizes of most 
human studies were small (n=5 in Klein’s study and n=18 in Sedman’s study) (Klein 
et al., 1984; Sedman et al., 1985).  The experimental models used to inspect the 
character of aluminum in PNAC tended to be in older animals (Klein et al., 1987; 
Dermican et al., 1998) and with aluminum doses much larger than the contamination 
levels found in the hospitals today (Klein et al., 1987; Dermican et al., 1998; 
Gonzalez et al., 2004).  Considering significant aluminum contamination exists, 
and the high risk of PNAC in infants, the proposed relationship requires further 
study. 
1.2 Objectives 
This study hypothesizes that aluminum is a contributing factor and plays an 
important role in PNAC in infants.  The main objectives of the study were: 
1. To investigate the role of aluminum in human infants who required PN.  
a. To monitor the relationship between serum aluminum and the development 
of PNAC. 
2. To set up an animal model to clarify the role of aluminum in PNAC by using 
different doses of intravenous aluminum or PN solutions.  This model will be a 
  5
neonatal model.  The doses of parenteral aluminum used in this model will be 
similar to the dose found in the infants who are on PN therapy.  
a. Develop a piglet model to study the relationship of aluminum and PNAC 
b. To compare different doses of aluminum in the development of cholestasis 
c. To determine if PN therapy with a known aluminum level is associated with 
the development of PNAC 
To achieve these, there were two parts of the research: one was a human infant 
observational prospective study, and the other was an experimental piglet model 
study.
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2. LITERATURE REVIEW 
2.1 Neonatal liver structure, functions and bile flow 
The liver is the largest solid organ in the body, constituting about 2% to 5% 
of the total body weight in adult and 5% in infant (Guyton, 2000).  The liver is 
provided with a dual blood supply of portal blood derived from the intestinal 
(splanchnic) circulation, and arterial blood (Guyton, 2000).  The basic functional 
unit of the liver is the lobule, a cylindrical structure, which is constructed around a 
central vein that empties into the hepatic veins and then into the vena cava.  The 
lobule itself is composed principally of many hepatic cellular plates.  Each hepatic 
plate is usually two cells thick, and between the adjacent cells are the small bile 
canaliculi that empty into bile ducts (Guyton, 2000).  The hepatic sinusoids lie 
between the hepatic plates.  The unique architectural arrangement of the 
intrahepatic vasculature into sinusoids interposed between hepatocytes greatly 
facilitates the exchange of material between blood and hepatocytes.  There is a set 
of cells including sinusoidal endothelial cells, Kupffer cells, hepatic cells, and 
natural killer cell (also known as Pit cells), which line the sinusoids (Guyton, 2000).  
The main structural characteristic of the sinusoidal endothelial cell lining is the 
occurrence of fenestrae, which controls the interchange between blood and 
perisinusoidal space.  Beneath this lining, lying between the endothelial cells and 
the hepatic cells is a narrow tissue space called the space of Disse.  This space 
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connects with lymphatic vessels in the interlobular septa and places fluid in direct 
contact with hepatocytes (Guyton, 2000). 
According to its structural organization, the liver has remarkable diverse 
functions, including (1) filitration and storage of blood; (2) metabolism of 
macronutrients, hormones and foreign chemicals; (3) formation of bile; (4) storage of 
vitamins and iron; and (5) formation of coagulation factors (Guyton, 2000).  The 
liver serves as the primary regulatory site for energy metabolism, taking up and 
processing ingested nutrients for controlled distribution to extrahepatic tissues.  In 
carbohydrate metabolism, the liver can store large amounts of glycogen, saving 
glucose while glucose in the blood is in excess.  Gluconeogenesis in the liver occurs 
when the glucose concentration falls below normal.  Therefore, the liver is 
especially important for maintaining a normal blood glucose concentration.  In 
infants, the gluconeogenesis function of the liver is not fully developed.  As a result, 
the blood glucose level of the unfed infant can fall to about 1.7 to 2.2 mmol·L-1, and 
the infant must depend on its stored fats for energy.  The conversion of galactose 
and fructose to glucose also occurs in the liver.  In addition, the liver synthesizes 
many important chemical compounds from intermediate products of carbohydrate 
metabolism.  The liver is responsible for a major part of lipid metabolism: by the 
oxidation of fatty acids to supply energy.  The liver also synthesizes large quantities 
of cholesterol, phospholipids, and most lipoproteins.  About 80% of cholesterol is 
converted into bile salts.  The remainder is transported in lipoproteins.  Both 
cholesterol and phospholipids are used by cells to form membranes, intracellular 
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structures, and multiple chemical substances that are important to cellular function.  
Almost all the lipid synthesis from carbohydrates and proteins occurs in the liver as 
well, and fat is then transported in lipoproteins to adipose tissue to be stored.  The 
liver is involved in protein metabolism: through the deamination of amino acids for 
gluconcogenesis, formation of urea for removal of ammonia from the body fluids, 
formation of plasma proteins, interconversions of the various amino acids, and 
synthesis of other compounds from amino acids (Guyton, 2000).  About 90% of 
plasma proteins such as albumin, transferrin, and prealbumin, are formed by the 
hepatic cells.  These proteins serve as transport proteins of drugs, nutrients, and 
hormones in addition to developing and maintaining plasma osmotic pressure.  In 
the inflammatory response, the liver synthesizes many acute phase proteins such as 
C-reactive protein, ceruloplasmin and the complement factors (Chwals, 1995).  
However, the liver of the infant is immature, so the plasma protein concentration 
falls during the first weeks of life to 15 to 20% less than that for older children 
(Guyton, 2000).  The liver also has the ability to synthesize the essential amino 
acids by transamination.  Furthermore, the liver has a particular propensity for 
storing vitamins, especially vitamins A and D.  Iron is stored as ferritin in the liver.  
A large proportion of the clotting factors used in coagulation are formed in the liver.  
The active chemical medium of the liver is well known for its capacity to detoxify or 
excrete into the bile many drugs, hormones and other substances. 
Bile secretion is a major function of the liver cell.  It is essential for 
excretion of endo- and xenobiotics, elimination of bilirubin and cholesterol, as well 
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as digestion and absorption of lipids and fat-soluble vitamins in the intestinal lumen 
(Scharschmidt, 2003).  Approximately 0.5 grams per day of bile salts are formed by 
the hepatocytes.  The primary constituents of bile are water, inorganic electrolytes, 
bile acids, cholesterol, phospholipids, and bilirubin (Gutyon, 2000).  Three 
components contribute to the bile flow: 1.bile acid-dependent bile formation; 2. bile 
acid-independent canalicular secretion; 3. bile acid-independent flow of ductal 
origin.   
Bile acid-dependent formation includes bile acid uptake, intracellular 
transport, and canalicular secretion by the hepatocyte (Kullak-Ublick et al., 2000).  
Bile acid uptake is mediated by two transporters: one is a sodium-dependent 
transporter, Na+-taurocholate cotransporting polypeptide (NTCP); the other one is a 
sodium-independent transporter, organic anion transporting polypeptide (OATP) 
(Hagenbuch et al., 1991; Jacquemin et al., 1994; Kullak-Ublick et al., 1995).  The 
energy for the NTCP is the transmembrane sodium gradient maintained by Na+, 
K+-ATPase on the basolateral membrane of the hepatocyte.  Canalicular secretion is 
medicated by an ATP-dependent transport system and a voltage-dependent carrier 
(Nishida et al., 1991; Muller and Jansen, 1997; Trauner et al., 1998).  The protein 
mediating ATP-dependent transport has been recognized as sister p-glycoprotein 
(spgp) (Gerloff et al., 1997; Trauner et al., 1998).  Active secretion of bile acids by 
hepatocytes provides an osmotic drive for canalicular water and electrolytes.  
Therefore, bile flow is formed by an osmotic gradient created within the lumen of the 
bile canaliculus between adjacent hepatocytes.  Bile acid is the most important 
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osmotically active solute.  It generates the bile acid-dependent flow, which accounts 
for about 50% of total bile flow in all species (Boyer et al., 1992).  Phospholipids 
are one part of bile acid-dependent flow and are transported by a protein of the 
multi-drug resistance (MDR) family: MDR3 (mdr2 in rodents).  This 
P-glycoprotein translocates phosphatidylcholine from inner to the outer leaflet of the 
canalicular membrane (Oude Elferink et al., 1995; Frijters et al., 1997).  
Canalicular excretion of glutathione and bicarbonate constitute the major 
components of the bile acid-independent fraction of the bile flow.  The canalicular 
multispecific organic anion transporter (cMOAT) participates in the transport of 
glutathione and glutathione conjugates into the canalicular lumen (Oude Elferink et 
al., 1995).  cMOAT is also referred to as multi-drug resistance-associated protein 2 
(MRP2) (Oude Elferink et al., 1996; Trauner, 1997).  Bilirubin is taken up by the 
hepatocytes by several carriers, including OATP.  After conjugation, the bilirubin is 
secreted into the canalicular lumen by cMOAT or MRP2 (Keppler et al., 1997; 
Trauner et al., 1998).  
Ductular bile flow is a bicarbonate-rich solution and is stimulated by secretin.  
Secretin receptors on the basolateral membrane of cholangiocytes bind secretin and 
activate cAMP production.  Increasing cAMP stimulates cystic fibrosis 
transmembrane conductance regulator (CFTR), a chloride channel on the apical 
membrane of cholangiocytes, to secrete chloride into the biliary lumen (Trauner et al., 
1998).  Chloride then activates a chloride/bicarbonate exchanger to increase 
bicarbonate secretion.  This exchanger is also located on the apical membrane.  
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Bile is modified by the bile ductules and ducts, and delivered to the intestine and/or 
gallbladder (Boyer et al., 1992, Trauner et al., 1998).  There is a linear relationship 
between bile flow and bile acid synthesis by the hepatocyte.  This production is in 
turn regulated by the return of bile salts to the liver through the enterohepatic 
circulation (The liver secretes primary and secondary bile salts into the duodenum.  
Along the proximal and distal ileum, primary bile salts are reabsorbed into the portal 
circulation.  This is called enterohepatic circulation) (Rees, 2002).  In infants of 
any gestational age, the relative size of total bile acid pool is reduced and multiple 
steps of the enterohepatic circulation are less efficient compared with those of the 
normal adult (Hofmann, 1995). 
Important advances have been made in recent years in the understanding of 
transport processes involved in bile formation as a result of cloning and 
characterization of several important transport proteins that mediate uptake, 
intracellular transport and secretion of organic compounds within the enterohepatic 
circulation (Muller and Jansen, 1997; Trauner et al., 1998; Hoffmaster et al., 2004) 
(Figure 2.1).  These transport systems on both basolateral and canulicular 
membranes are involved in the mechanism of bile flow (Table 2.1).  Any alteration 
of these transporters may cause an abnormality of bile flow (Lecureur et al., 2000). 
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Table 2.1 Function of transport proteins in bile formation  
(Adapted from Muller and Jansen, 1997) 
 
Transporter Location Function 
Bile acid-dependent bile flow 
NTCP Basolateral 
membrane 
Hepatic uptake of bile acids 
Na+-K+ ATPase Basolateral 
membrane 
Removal of 2 Na+ in exchange for 3 
K+, thus creating a favorable Na+ 
gradient 
cBAT (spgp) Canalicular 
membrane 
ATP-dependent canalicular transport of 
bile acid 
MDR3 Canalicular 
membrane 
ATP-dependent canalicular transport of 
phosphatidylcholine 
Bile acid-independent bile flow 
OATP Basolateral 
membrane 
Hepatic uptake of organic anions, 
neutral steroids, and type II organic 
cations 
Na+-K+ ATPase Basolateral 
membrane 
See above, creates a favorable 
electro-chemical gradient for GSH 
transport 
MRP2 Canalicular 
membrane 
ATP-dependent canalicular transport of 
GSH-, glucuronide- and 
sulfate-conjugates and perhaps GSH 
Ductular secretion 
Cl-/HCO3- 
exchanger 
Apical membrane HCO3- secretion in exchange for Cl- 
Cl- channels 
e.g., CFTR 
Apical membrane Cl- secretion 
NTCP, human Na+-taurocholate cotransporter;  OATP, human organic anion 
transporting polypeptide;  CFTR, cystic fibrosis transmembrane conductance 
regulator;  cBAT, canalicular bile acid transporter;  MDR3, multidrug resistance 
(MDR) protein 3;  MRP1, human MDR protein;  MRP2, human MRP1 
homologue;  GSH, glutathione.   
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PL 
NTCP: sodium taurocholate transporting polypeptide 
OATP: organic anion transporting polypeptide 
MDR1: multidrug-resistance-1 P-glycoprotein 
MDR3: phospholipid transporter multidrug-resistance-3 P-glycoprotein 
MRP2 or cMOAT: canalicular multispecific-organic-anion transporter 
SPGP or BSEP: canalicular bile-salt-export pump 
AE2: chloride-bicarbonate anion exchanger isoform 2 
CFTR: cystic fibrosis transmembrane regulator 
PL: phospholipid 
OA-: organic anion 
BS-: bile salt 
OC+: organic cation 
A-: anion 
Figure 2.1  Transport system in the hepatocyte and cholangiocyte (Modified from
Trauner et al., 1998) 
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2.2 Bilirubin metabolism in infants 
Bilirubin is the degradation product of heme from red cells, as well as from 
muscle myoglobin and certain liver enzymes such as cytochromes and catalases.  
The first step in the breakdown of heme is catalyzed by heme oxygenase, an enzyme, 
which is found in the reticuloendothelial system, and in tissue macrophages as well 
as gut mucosa.  The following step, reduction at the central C-10 carbon of 
biliverdin IXα to form bilirubin is catalyzed by biliverdin reductase in the cytosol 
(Tenhunen et al., 1969).  Unconjugated bilirubin is transported in plasma bound to 
albumin.  The binding of bilirubin to albumin increases with postnatal age, but it is 
reduced in sick infants and the presence of exogenous or endogenous binding 
competitors (Robertson et al., 1981).  When the bilirubin-albumin complex passes 
through the hepatic circulation, bilirubin but not albumin is transported into the liver 
cell.  There is an albumin receptor on the hepatocyte surface, and several transport 
proteins in the sinusoidal liver cell plasma membrane may be mediated in the 
transportation of bilirubin into the hepatocyte (Wolkoff et al., 1979).  The principal 
bilirubin intracellular binding protein is ligandin, a glutathione S-transferase 
(Wolkoff et al., 1978).  In monkeys, ligandin concentrations in the liver are low at 
birth but appear to reach adult values within 1-2 weeks (Levi et al., 1970).  The 
bound bilirubin is then transferred to the smooth endoplasmic reticulum (SER) where 
conjugation takes place.  The conjugation is catalyzed by bilirubin 
uridinediphosphoglucuronate glucuronosyl transferase (UDPGT), forming bilirubin 
monoglucuronide and diglucuronide.  The role of this process is to convert the 
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water-insoluble unconjugated bilirubin to a water-soluble form, which can be 
excreted in the bile.  The activity of UDPGT at birth is only 1% of adult values 
(Kawade and Onishi, 1981).  Excretion of conjugated bilirubin into bile is an energy 
requiring process against the concentration gradient.  When these conjugates are in 
the bile, they are subsequently transformed to urobilinoids through bacterial action in 
the gut lumen.  Conjugated bilirubin may also undergo de-conjugation through the 
action of a β-glucuronidase, and the unconjugated bilirubin can then be reabsorbed 
through the intestinal mucosa back to the enterohepatic circulation.  Alternate 
metabolic pathways for bilirubin may exist but are not currently known in human 
infants (Hansen, 2000).  A schematic illustration of bilirubin metabolism is shown 
in Figure 2.2. 
Almost every newborn infant will develop a serum unconjugated bilirubin 
>30 µmol·L-1 (1.8mg·dL-1) during the first week of life.  In general, the bilirubin 
level peaks between the 3rd and 5th days of life and declines thereafter (Maisels, 
1988).  In the infant the daily production of bilirubin is estimated to be about 8.5 
mg·kg-1, which is more than double the production rate in adults (Maisels, 1988).  
The deficiency of ligandin in the infants may decrease the ability to retain bilirubin 
inside the hepatocyte and consequently may cause bilirubin to reflux into the 
circulation.  However, there is no evidence that it is implicated in pathological 
jaundice (Hansen, 2000).  The activities of UDPGT are low at birth and increase in 
early life to reach adult values at 14 weeks of age (Kawade and Onishi, 1981).   
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Figure 2.2  Bilirubin Metabolism  
(Modified from Scharschmidt, 1982; Hansen, 2000) 
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In the first 3-4 days of life, conjugation is the rate-limiting step in bilirubin 
metabolism.  Then the following next few days hepatic uptake and excretion are 
limiting, after that, excretion is the rate-limiting step during the rest of life (Hansen, 
2000).  Fluid and nutrient intake is limited in the newborn until breast milk 
production is established.  As a result, there is a lack of binding vehicle in the 
intestinal lumen to transport bilirubin conjugates through the gut.  The infant is born 
with a sterile gut, and the lack of the intestinal microbial flora decreases further 
breakdown of bilirubin and fecal urobilinoids excretion.  In infants who are kept off 
oral feeds for reasons of severe illness, and in infants receiving inadequate nutrition, 
enterohepatic circulation is enhanced.  It is possible that increased enterohepatic 
circulation is involved in the mechanism of neonatal jaundice (Hansen, 2000).  
Physiologic jaundice occurres in infants due to the increased breakdown of red blood 
cells in the presence of a low capacity for uptake, conjugation and excretion of 
bilirubin in the liver, as well as reabsorption of bilirubin from the gut because of the 
relatively low nutrient intake and thus reduced intestinal transit in the first few days 
of life (Hansen, 2000).  However, the distinction between physiologic and 
pathologic jaundice in infants is often not clear.  Each of the normally occurring 
mechanisms that produce hyperbilirubinemia may be exaggerated by both 
endogenous and exogenous factors. 
2.3 Neonatal cholestasis 
2.3.1 Pathophysiology of cholestasis  
Cholestasis is a form of liver injury and is defined by a decrease or absence of 
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bile flow into the duodenum (Erlinger, 1999).  The retention of bile in the liver 
causes hepatocyte injury.  Morphologically, bile pigment can usually be found in 
hepatocytes, canaliculi, and sometimes Kupffer cells (Erlinger, 1999).  Cholestasis 
may be caused by obstruction of the extrahepatic bile ducts, obstruction of the 
intrahepatic bile ducts, or alteration of the patterns of the secretion of bile by the 
hepatocytes (Table 2.2) (Erlinger, 1999).  Up to 50% of the neonatal cholestasis was 
due to genetic/metabolic diseases or parenteral nutrition (Stormon et al., 2001). 
Extrahepatic cholestasis 
The main reason for extrahepatic cholestasis is obstruction of extrahepatic 
bile ducts.  Dilatation of bile canaliculi with a loss of microvilli and alterations of 
intercellular junctions can be found in the bile duct ligation cholestasis model.  
These alterations increase canlicular permeability and allow a “regurgitation” of bile 
constituents into hepatic lymph and blood (Accatino et al., 1981).  Bile duct ligation 
also induces modifications in hepatocytes.  Various enzymes and carriers of the 
hepatocyte plasma membrane are redistributed to the sinusoidal and lateral pole of 
the cell.  The modified polarity of the membrane causes the substrates to re-secrete 
into blood after their entry into the hepatocyte.  Because of the change in hepatocyte 
metabolism, alkaline phosphatases and cholesterol production increase.  Jaundice is 
severe in this kind of mechanical biliary obstruction.  Bile pigment may be seen in 
the lumina of cholangioles or acinar bile ducts (Erlinger, 1999).  When biliary 
obstruction is prolonged, it leads to bile ductular proliferation, fibrosis, and 
secondary biliary cirrhosis (Erlinger, 1999).  The specific mechanisms of ductular  
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Table 2.2  Common causes of cholestasis (Adapted from Erlinger, 1999) 
 
1. Causes of obstruction of extrahepatic bile ducts 
Common bile duct stone 
Pancreatic carcinoma, chronic pancreatitis, pancreatic cyst 
Carcinoma of the ampulla of Vater 
Bile duct strictures 
Parasites 
Primary sclerosing cholangitis 
AIDS cholangiopathy 
Portal vein thrombosis 
Hodgkin’s disease, lymphoma 
Choledochal cyst 
Biliary atresia 
2. Causes of obstruction of intrahepatic bile ducts 
Primary biliary cirrhosis 
Space-occupying lesions 
Primary or secondary liver cancer 
Lymphoma  
Amyloidosis 
Vanishing bile duct syndrome 
Allograft rejection 
Graft-versus-host disease 
Alagille’s syndrome  
Idiopathic adult ductopenia 
Primary sclerosing cholangitis 
Hodgkin’s disease 
Cystic fibrosis 
3. Causes of hepatocellular cholestasis 
Genetic 
α1-antitrypsin deficiency 
Byler syndrome 
Abnormal bile acid synthesis 
Porphyria 
Cholestasis of pregnancy 
Benign recurrent intrahepatic cholestasis 
Acquired 
Pure cholestasis without hepatitis: drugs (i.e., estrogen) 
Cholestatic hepatitis: virus, drugs, alcohol 
Bacterial infections 
Total parenteral nutrition 
Paraneoplastic cholestasis: renal carcinoma, Hodgkin’s disease 
Miscellaneous  
  20 
 
proliferation and fibrosis are not clear.  In animals, the changes observed after 
biliary obstruction are reversible when obstruction is relieved and adequate bile flow 
is restored (Zimmermann et al., 1992).  
Intrahepatic cholestasis 
Intrahepatic cholestasis may result from obstruction of intrahepatic bile ducts 
or from alteration of bile secretion by the hepatocytes (hepatocellular cholestasis).  
For obstruction of intrahepatic bile ducts, the mechanisms are basically the same as 
the exrahepatic obstruction with the exception of cystic fibrosis.  The function of 
cystic fibrosis transmembrane conductance regulator (CFTR) is impaired with 
decreased chloride and bicarbonate secretion (Roy et al., 1982).  This leads to a 
decrease in ductal bile flow.  The decreased bile flow results in mucous 
precipitation and obstruction of small bile ducts.  The consequence of obstruction is 
ductular proliferation, inflammation, focal fibrosis, and focal biliary cirrhosis (Roy et 
al., 1982).  Regarding hepatocellular cholestasis, the impairment of bile secretion by 
the hepatocytes may be due to hemodynamic disturbances or alteration of the 
sinusoidal, intracellular, or canalicular steps of the hepatic transport of bile (Eringler, 
1999).  A foamy transformation of the cytoplasm of hepatocytes, Kupffer cells, and 
biliary epithelial cells can be seen in the prolonged cholestasis.  Many disorders, 
including alcoholic liver disease, drug-induced hepatotoxicity, viral hepatitis, and 
various developmental and metabolic diseases, can be associated with intrahepatic 
cholestasis (Eringler, 1999). 
In infants, several factors contribute to decrease bile flow including 
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inefficient bile acid intake, impaired bile acid conjugation, qualitative and 
quantitative deficiencies of bile acid synthesis, and decreased hepatocellular 
excretion (Table 2.3).  Immaturity of hepatic function creates the potential for 
further decreases in bile flow in response to any insult in infants, such as endotoxin 
or parenteral nutrition (Gremse and Balistreri, 1989).  In addition, other conditions 
including prematurity, hypoxia, hypoperfusion, sepsis, hepatitis, and fasting, may 
further impair hepatic excretory function (Btaiche and Khalidi, 2002). 
2.3.2 Molecular mechanisms of cholestasis 
In general, cholestasis results from defects in the regulation and expression of 
the membrane transporters that generate bile secretion and from cellular events that 
impairs signal transduction pathways, cytoskeletal structures, tight and gap junctions, 
and the targeting of intracellular vesicles (Shaffer, 2002; Hyogo et al., 2001).  
Results of recent molecular studies indicate that decreased expression of transport 
systems contributes significantly to the impairment of transport functions that result 
in or maintain cholestasis (Crocenzi et al., 2003; Geier et al., 2005; Lee et al., 2000; 
Geier et al., 2003).  Some of these defects are related to hereditary defects by which 
mutations or polymorphisms result in impairment of transporter protein expression 
(Table 2.4).  In rats with obstructed bile ducts, expression of ntcp and oatp (NTCP 
and OATP in human), which are responsible for bile acid uptake, is reduced due to a 
decrease in transcription (Gartung et al., 1996; Dumont et al., 1997).  The 
down-regulation could prevent the accumulation of potentially toxic bile acids and 
organic anions within the hepatocytes (Geier et al., 2005).  The down-regulation of  
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Table 2.3  Manifestations of underdeveloped bile acid transport and 
metabolism in infants (Gremse and Balistreri, 1989) 
 
Serum bile acid levels are increased 
Hepatic uptake of bile acids is decreased 
Bile acid efflux is enhanced 
Lobular gradient is absent 
Conjugation, sulfation, glucuronidation are decreased 
Qualitative and quantitative defects in synthesis are present 
Bile acid pool size is decreased 
Bile acid secretion rate is decreased 
Intraluminal concentrations of bile acid are low 
Ileal active transport of bile acids is low 
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Table 2.4  Molecular changes of hepatocellular transport systems in humans 
(Scharschmidt, 2003; Elferink and Groen, 2002;Trauner et al., 1998) 
 
Disease Molecular Change 
Hereditay: 
Progressive familial intrahepatic 
cholestasis(PFIC) 
PFIC-1(low serum γ-glutamyltransferase) 
PFIC-2(low serum γ-glutamyltransferase) 
PFIC-3(high serum γ-glutamyltransferase) 
 
 
Benign recurrent intrahepatic 
cholestasis(BRIC)  
 
Dubin-Johnson syndrome 
 
Acquired: 
Primary biliary cirrhosis 
 
 
 
 
Extrahepatic biliary atresia 
 
 
 
 
 
Primary sclerosing cholangitis 
 
 
 
Extrahepatic biliary obstruction  
 
 
 
 
Mutation in P-type ATPase 
Mutation of BSEP gene 
Canalicular BSEP protein absent 
Canalicular MDR3 protein absent 
 
Mutation in P-type ATPase  
 
 
Canalicular MRP2 protein absent 
 
 
AE2 mRNA and protein reduced; 
hepatocytes and cholangiocytes are 
affected; MDR3 mRNA levels 
unchanged 
 
NTCP mRNA reduced. Inverse 
correlation with serum bilirubin 
levels; increase after successful 
Kasai procedure. BSEP protein 
maintained at canalicular 
membrane 
 
OATP mRNA increased, possibly 
diminishing hepatic retention of 
organic anions 
 
MDR1 and MDR3 mRNA 
increased. Direct correlation with 
serum bilirubin levels. 
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cmoat (mrp2) (MRP2 in human) could contribute to impair biliary excretion (Trauner, 
1997).  However, most of the alterations that occur in both hereditary and acquired 
cholestatic disorders are secondary responses rather than primary causative changes.  
The expression of specific membrane transporters adapts to a variety of forms of 
cholestatic liver injury in a manner that tends to diminish the hepatic uptake of bile 
salts from portal blood, while at the same time maintaining or in some instances 
up-regulating mechanisms that may help to facilitate the exit of bile salts and other 
toxic substances from hepatocytes.  Thus, transporters on the basolateral sinusoidal 
membrane that normally function to selectively remove bile salts and other 
substances from portal blood are usually down- regulated during cholestasis by 
transcriptional or posttranscriptional mechanisms (Gartung et al., 1996; Dumont et 
al., 1997; Trauner et al., 1998; Lee et al., 2000).  On the other hand, some 
canalicular transport proteins, particularly the MDR homologues, are either not 
impaired or may actually be up-regulated (Bhunchet and Fujieda, 1993; Tazuke et al., 
2004).  
Profound changes in the cytoskeleton of the hepatocytes, including disruption 
of microtubules, increases in intermediate filaments, and accumulation of 
disorganized bundles of actin microfilaments in the pericanalicular domain, are 
shown in most human and animal cholestatic liver disorders (Hyogo et al., 2001).  
These changes result in the loss of apical microvilli and diminished contractility of 
the canalicular membrane and may also contribute to the leakiness of tight junctions 
between cells (Trauner et al., 1998).  
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2.3.3 Parenteral nutrition associated cholestasis 
2.3.3.1 Overview 
Since the development of parenternal nutrition (PN) about three decades ago, 
many patients who are unable to tolerate food have survived and recovered.  PN has 
become a vital tool in the supportive care of premature and critically ill infants.  
Although undoubtedly life-saving in many instances, PN is associated with several 
complications, including metabolic imbalance, recurrent thromboembolism, and liver 
dysfunction (Taylor et al., 1991; Kelly, 1998).  Parenteral nutrition associated 
cholestasis (PNAC) is one of the most common complications in infants which 
accounts for appreciable morbidity and occasional mortality (Kelly, 1998).  The 
incidence has been reported from 7.4% to 84% of the patients receiving PN (Beath et 
al., 1996; Teitelbaum et al., 2001).  The wide variations in the frequency reported 
may be due to the nature of the patient population studied and many other 
confounding factors, such as gastrointestinal surgery, prematurity, the duration of PN, 
different diagnostic standards and the presence of sepsis.  25% of the 
gastrointestinal failure infants developed PNAC was found in our unpublished data 
(Arnold, 2004).  A recent study in Japan found an incidence of 25% from 1992 to 
1996 with an associated mortality of 3% in their neonatal wards (Kubota et al., 2000).  
Kelly’s research in children on long-term PN shows that 40% to 60% of patients 
develop some degree of hepatic dysfunction (Kelly et al., 1998). 
Clinically, a conjugated hyperbilirubinemia with elevations in levels of 
alkanine phosphatase (ALP) and serum aminotransferases may be present.  Jaundice 
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and hepatomegaly are the most common physical findings.  The diagnosis of PNAC 
is made after other causes of neonatal cholestasis have been excluded (Gremse and 
Balistreri, 1989).  Histological changes are nonspecific and vary considerably 
among patients (Btaiche and Khalidi, 2002; Zambrano, et al., 2004).  Giant cell 
transformation, hepatocellular damage, extramedullary hematopoiesis, portal fibrosis, 
changes characteristic of neonatal hepatitis may be observed.  These changes can be 
noted within 10 days of PN introduction (Briones and Iber, 1995; Hodes et al., 1982; 
Dahms and Halpin, 1981).  
Biochemical abnormalities may persist for months after jaundice is resolved.  
This places the infant at risk for chronic liver disease and its complications.  Less 
than 10% of PNAC patients progressed to cirrhosis, portal hypertension and liver 
failure (Kubota et al., 2000).  The risk factors for the progression are not well 
delineated.  Because of the lack of understanding of the etiology of PNAC, the 
treatment of most patients is empiric and supportive.  Available evidence suggested 
that discontinuation of PN and institution of enteral feeding were useful for resolving 
PNAC, but not all (Kelly, 1998; Hodes et al., 1982; Moss et al., 1993; Dermican et 
al., 1999;).  Cycling of PN, ursodeoxycholic acid (UDCA) and phenobarbital or 
prophylactic antibiotics has been used with some success (Capron et al., 1993; 
Collier et al., 1994; Spagnuolo et al., 1996; Chen et al., 2004). 
2.3.3.2 Potential factors in neonatal parenteral nutrition associated cholestasis 
The pathogenesis of PNAC is still unclear.  Recently most of the studies 
suggest that the causes of this disease in infants often are multifactorial (Drongowski 
  27 
 
and Coran, 1989; Beath et al., 1996; Kubota et al., 2000; Btaiche and Khalidi, 2002). 
PNAC typically occurs in the clinical setting of multiple factors that may damage the 
liver.  Premature birth, duration of PN, lack of enteral feeding, sepsis, imbalanced 
nutrients, potentially toxic drugs, and contamination of PN solutions may all 
contribute to PNAC (Figure 2.3).  However, in individual patients, the relative 
contribution of each of the potential factors is highly variable (Merrit, 1986; Btaiche 
and Khalidi, 2002). 
Beale et al. (1979) found the incidence of PNAC in a series of 62 infants was 
23% overall, with an incidence of 50% in infants with birth weight under 1000g; 
18% in those from 1000 to 1499 g; and 7% in those from 1500 to 2000 g.  Several 
studies concur that PNAC is more common in extremely low birth weight or 
premature infants (Kelly, 1998).  It has been suggested that the immaturity of the 
hepatobiliary system may play a role in PNAC.  The relative reduced pool size of 
total bile acid, low specific enzyme activity, ineffecient hepatocyte uptake and 
excretion of bile acids, and immature enterohepatic circulation can decrease the bile 
flow (Hofman, 1995; Farrell and Balistreri, 1986).  However, these immaturities 
also exist in infants of any gestational age.  The agreement is the high risk of PNAC 
in infants because of these physical immaturities.  In a retrospective study, 17 of 32 
infants who received PN therapy at least 7 weeks developed cholestasis (Drongowski 
and Coran, 1989).  There were significant differences between the cholestasis and 
noncholestasis infants in number of operations (13 vs 6, p = 0.0407), and days until 
enteral feedings were started (33.1 vs18.9, p = 0.0289).  However, no difference  
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Figure 2.3   Potential factors of PNAC in infants  
(Modified from Gremse and Balistreri, 1989) 
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was found in birth weight, gestational age, days from birth to the start of PN, or 
respiratory distress in the study (Drongowski and Coran, 1989).  The relationship 
between the premature birth and PNAC is still not well delineated.  More studies 
need to be done to define the birth weight or gestation age and the contribution to 
PNAC. 
Lack of enteral feeding is one feature of PN and recognized by some studies 
as a risk factor in PNAC (Drongowski and Coran, 1989; Quigley et al., 1993; 
Hofmann, 1995).  The mechanism was thought that because of absent substrate, the 
normal pattern of interdigestive migrating motor complex is not maintained, and 
intestinal motility is slow.  The secretion of the hormones cholecystokinin (CCK) 
and secretin is decreased.  CCK is responsible for gallbladder contractility thus 
preventing biliary sludge formation (Spagnuolo et al., 1990).  Moreover, fasting 
leads to atrophy of the enterocytes and decreased ileal absorption of the primary bile 
salt taurocholate (Matsumura et al., 1993).  The decreased absorption of bile acids 
from the gut resulted in increased concentrations of cholestatic secondary bile acids 
which are toxic bile acids causing cholestasis (Foulin-Fortunet et al., 1982).  
Although researchers recognized the possible mechanism of lack of enternal feeding 
in PNAC, the results from further studies seem to be controversial.  Increasing the 
CCK levels did not significantly reduce the incidence of PNAC (Aynsley-Green et 
al., 1983; Moss and Amii, 1999; Teitelbaum et al., 2005).  Other researches in 
addition demonstrated that the use of enteral feeding didn’t improve the symptom of 
progressive PNAC, especially intrahepatic cholestasis (Hodes et al., 1982; Moss et 
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al., 1993; Dermican et al., 1999).  Two review studies also pointed out that enteral 
starvation did not correlate significantly with the development of PNAC in infants 
(Beath et al., 1996; Zambrano et al., 2004).  At this point, the role of lack of enteral 
feeding in PNAC is still contentious. 
Sepsis has been found to be associated with an increased risk of PNAC 
(Moss et al., 1996; Beath et al., 1996).  The researchers found that episodes of 
sepsis were associated with a 30% increase in the bilirubin level.  The septic events 
that happened in the PNAC infants were significantly higher than the non-cholestatic 
infants (Beath et al., 1996).  In one series including infants on short-term PN, the 
incidence of cholestasis was 26% in those with infection, and it did not occur in 
those without infection (Wolf and Pohlandt, 1989).  The theory of sepsis in PNAC 
is thought to be an endotoxin which is produced by gram-negative bacteria and 
causes the release of cytokine such as tumor necrosis factor-α and interleukin-I 
(Beath et al., 1996).  The used of antibody against tumor necrosis factor-α 
improved the PNAC in the case report (Forrest et al., 2002).  More clinical trials are 
needed to verify the treatment of PNAC.  Animal studies have demonstrated that 
bacterial endotoxins cause inflammation and fibrosis in the liver.  However, a 
pathology study in 24 infants showed that there was no significant relationship 
between sepsis and liver injury (Zambrano et al., 2004).  The exact mechanism on 
which sepsis leads to cholestasis remains unclear. 
The nutritional components of PN solutions are always prominent on the list 
of suspected contributors to PNAC.  There has been significant research attempting 
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to define the role of the individually infused nutrient in the pathogenesis of 
cholestasis (Forchielli and Walker, 2003).  
Investigators found that the incidence of cholestasis was directly related to 
the volume of amino acids infused by affecting the canalicular membrane of the 
hepatocyte (Black et al., 1981; Merritt, 1986; Kelly, 1998).  In a prospective 
controlled study, infants with high amino acid infusion (3.6 g·kg-1·day-1) developed 
PNAC earlier (27 days, p<0.01) than the low amino acid infusion (2.3 g·kg-1·day-1) 
group and achieved a significantly greater peak direct bilrubin level (143 µmol·L-1 
versus 54.4 µmol·L-1, p<0.001) (Vileisis et al., 1980).  In rats, a high concentration 
of glycine, a sodium-dependent transport amino acid, inhibits the hepatic basolateral 
membrane uptake of the bile acid taurocholate (Bucuvalas et al., 1985).  
Alternatively, the deficiencies of specific amino acids, such as taurine, have been 
suggested as possible causes of PNAC (Dorvil et al., 1983).  Taurine is an essential 
amino acid for infants due to a relative lack in the enzyme cystathionase for 
synthesis.  Taurine is the primary amino acid used for conjugation of bile acids.  
The deficiency of taurine in PN solutions may contribute to the development of 
PNAC.  However, there is little supporting evidence to indicate that the pediatric 
amino acid solutions which include taurine have reduced the incidence of PNAC in 
infants.  Methyl donor amino acids, such as methionine or serine have been 
evaluated in cholestasis with mixed results.  Belli et al. (1987) suggested that the 
additional methionine or serine may protect against the development of PNAC, 
whereas others found that methionine may be toxic to the liver (Coran et al., 1987; 
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Moss et al., 1993).  Recently published studies also suggested that PNAC was 
associated with the different type of amino acid solution administered (Suita et al., 
2002; Wright et al., 2003).  However, which type of formulation may be less likely 
to cause PNAC needs further study. 
Carbohydrate overload may overwhelm the hepatic glucose-oxidizing 
capacity and could cause hepatocellular enlargement and other hepatic injuries.  
The damages of liver cells are sufficient to compress the canaliculi and obstruct bile 
flow (Hirai et al., 1979).  But in adults, carbohydrate overload produces steatosis 
not cholestasis.  A study from Japan investigated the dextrose overload and the 
effects of amino acids in PNAC in newborn rabbits.  PNAC was found in the high 
dose dextrose group (25 g·kg-1·day-1) (Hata et al., 1993).  However, this same study 
also showed that PNAC was prevented by adding an appropriate volume of amino 
acids.  Considering the PN solutions used in the hospitals now, carbohydrate 
overload is rare.  
The lipid emulsions also have been investigated.  The association between 
lipid emulsions and PNAC was reported in children on the long-term parenteral 
nutrition (Colomb et al., 2000).  Conversely, other studies showed a protective 
effect of lipid emulsions on the liver when a balanced nutritional regimen was 
provided (Oshita et al., 2004; Reif et al., 1991).  A recent study found that fish oil 
based lipid emulsions can reduce the incidence of PNAC compared with 
soybean-derived emulsions in neonatal piglets (Van-Aerde et al., 1999).  It is 
thought that different fatty acid composition may modify bile composition due to the 
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changes of hepatocyte membrane composition and function.  Plant sterol is another 
lipid component that has been investigated.  Lipid hydroperoxides and phytosterols 
have been measured in high levels in lipid emulsions.  Plant sterols may relate to 
the histologic evidence of peroxidation of cell membranes and have been shown to 
cause a reduction in bile secretion in experimental models (Wispe et al., 1985; Iyer et 
al., 1998).  The lipid now used in the clinics is a mixed emulsion with soybean oil 
and egg phospholipids.  Little evidence is available in human studies.  In fact, 
cholestasis was reported in infants before the routine use of parenteral lipid 
emulsions in nutritional support (Farrell et al., 1986).  This suggests that fat 
emulsions may contribute to PNAC but probably are not the major cause of PNAC.   
Trace minerals including zinc, manganese, copper, chromium, selenium and 
iodine are added to PN solutions (ASCN/ASPEN, 1991).  Because some of the 
trace minerals are excreted in bile, such as manganese and copper, patients with 
pre-existing hepatic dysfunction are at particular risk for toxicity (Reynolds et al., 
1994; Ferenci et al., 2002).  The accumulation of manganese and copper in the liver 
associated with high blood concentrations has been documented in adults and 
children on PN (Kelly, 1998; Shike et al., 1981; Fok et al., 2001).  It is uncertain 
whether high serum levels lead to cholestasis or are the result of decreased mineral 
secretion in bile. 
2.4 The toxicity of aluminum 
There is evidence that the contaminants of PN solutions, such as aluminum, 
may play a role in PNAC.  Details of aluminum in PNAC will be discussed in the 
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following section. 
2.4.1 Metabolism of aluminum 
Aluminum is the third most abundant element of the earth’s crust.  The 
intake of aluminum from natural sources with food and beverages accounts for 
90-95% of the total daily intake in most adults.  The absorption of aluminum via 
the gastrointestinal tract is generally less than 1% (Greger and Sutherland, 1997).  
Parenteral aluminum exposure usually occurs via contaminated PN solutions, some 
intravenous (iv) drugs, and blood products such as albumin. 
After absorption, aluminum is bound in the plasma primarily to transferrin, 
and to a lesser extent to albumin, as well as in free form (Bertholf et al., 1984; 
Greger and Sutherland, 1997).  Aluminum can then be delivered to the liver by 
transferrin (Greger and Sutherland, 1997; Klein et al., 1993).  The accumulation of 
aluminum in lysosomes of macrophages and in lipofuscin granules as well as in the 
phagolysosomes of hepatocytes has been found under electron microscopy.  These 
depositions of aluminum created severe ultrastructural lesions in the liver cells 
(Fiejka et al., 1996; Galle et al., 1987). 
The major route of aluminum elimination is by urine and a small amount 
excreted in bile.  Most blood aluminum is cleared in the urine in healthy adults 
(Greger and Sutherland, 1997).  The excretion data in infants is insufficient.  
However, infants have immature renal function that may negatively effect aluminum 
excretion.   
The toxicity of aluminum was first described in uremic patients undergoing 
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hemodialysis (Berlyne et al., 1970).  Subsequently toxic effects due to high 
aluminum body loads were observed in several conditions.  The risk of aluminum 
toxicity is dependent on the length of exposure, the dose and renal function.  
Aluminum toxicity has also been implicated in the pathogenesis of several diseases, 
including PNAC, Alzheimer’s disease, Parkinson’s disease, and osteomalacia (Klein 
et al., 1995; Koo, 1992; Savory et al., 1996). 
2.4.2 Aluminum in parenteral solutions 
Aluminum contamination of PN solutions was first identified in 1982, 
notably in the casein hydrolysate, which was the protein source at the time.  
Aluminum was found in urine, blood, and bones of patients receiving these solutions 
(Klein et al., 1982).  The same research group also identified the aluminum level in 
the PN solutions delivered to the patients in the neonatal intensive care unit 
contained 327±130 µg·L-1, which would deliver approximately 30 µg·kg-1·day-1 to a 
preterm infant (Klein et al., 1991).  ASCN-ASPEN Working Group recommended 
that aluminum intake below 2 µg·kg-1·day-1 was safe, 15-30 µg·kg-1·day-1 was unsafe 
and 60 µg·kg-1·day-1 was toxic for adults (ASCN/ASPEN, 1991).  For infants, 
several studies suggested that the toxic level for parenteral aluminum intake was 
much lower that the adult level.  Bishop et al. (1997) demonstrated that loads of 
15-30 µg·kg-1·day-1 in PN solutions given to premature infants began to approximate 
toxic levels.  The aluminum content in PN solutions ranged from 112 to 196 µg·L-1, 
representing a mean daily intake of 16.7 µg·kg-1·day-1 in neonatal patients (Moreno 
et al., 1994).  A more recent study showed that the contamination levels of 
  36 
 
aluminum in PN solutions were higher, particularly in calcium salts, phosphates, and 
trace elements (Popinska et al., 1999).  Aluminum content was also found in 
heparin and blood products such as albumin (Recknagel et al., 1994; Davis et al., 
1999).  In 2000, the Food and Drugs Administration (FDA) of the United States of 
America published guidelines for aluminum contamination of PN solutions.  Large 
volume solutions should not contain more than 25 µg·L-1 aluminum.  For small 
volume solutions, the maximum level of aluminum must be stated on the label (FDA, 
2000). 
2.4.3 Aluminum and parenteral nutrition associated cholestasis 
There was some evidence of hepatic aluminum accumulation in children and 
infants who received PN.  In 1984, Klein et al. (1984) investigated 5 children, aged 
18 to 34 months, who developed PNAC while on PN for 18 to 33 months.  Liver 
enzymes (SGOT, SGPT, ALP), total or direct bilirubin were increased.  They also 
found elevated serum, urine, and hepatic aluminum levels in these patients.  
Hepatic aluminum accumulation ranged from 5 to 27 times normal concentrations. 
Histopathology of liver biopsies from these patients demonstrated periportal fibrosis, 
bile duct proliferation, inflammatory cells, cellular necrosis and nonuniform nodular 
regeneration (Klein et al., 1984).  Sedman et al. (1985) prospectively studied 18 
premature infants on PN and compared with 8 term infants without intravenous 
therapy.  They found premature infants who were on PN had high plasma and 
urinary aluminum concentrations as compared with normal controls.  In 1994, 
Moreno et al. (1994) reported an observational study of 35 infants who required PN.  
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The average duration of PN was 15.6±8.7 days.  Similar aluminum accumulation 
results were found in blood and urine samples.  Aluminum accumulation in tissue 
was confirmed in 3 infants whom aluminum levels were studied in autopsy samples.  
In addition, they showed that PN solutions were the main source of aluminum 
representing 88.7% of total aluminum intake (Moreno et al., 1994).  Based on the 
evidence of aluminum accumulation in infants who received PN, elevated liver 
enzymes and total/direct bilirubin, high serum and urine aluminum level, as well as 
histology findings in PNAC infants, researchers concluded that aluminum loading 
could contribute to the pathogenisis of PNAC (Klein, 2003). 
Several animal models have been used to further study aluminum in PNAC.  
Klein et al. (1987) followed their human studies by using a piglet model to 
investigate the relationship of aluminum and PNAC.  Eight piglets, 6 weeks old, 
were divided into experimental and control groups.  The experimental group was 
given parenteral aluminum 1.5 mg·kg-1·day-1 while the control group received 
heparinized saline for 50 days.  At the end of the study, serum total bile acid levels, 
mean alkaline phosphatase (ALP), and hepatic aluminum levels were significantly 
elevated in the experimental piglets, indicating that cholestasis may have developed.  
The deposit of aluminum in hepatocyte lysosomes of the experimental animals was 
also seen by electron microscopy (Klein et al., 1987).  In 1988, the same research 
group studied different doses and duration of exposure of aluminum associated 
hepatobiliary dysfunction in rats.  Three experimental groups received intravenous 
aluminum as follows: 1. 5 mg·kg-1·day-1 for 14 days; 2. 1 mg·kg-1·day-1 for 14 days; 
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3. 5 mg·kg-1·day-1 for 7 days.  The control animals received saline.  After the 
experiment period, bile and urine were collected for 3 hours.  They found that 
hepatic aluminum levels and total serum bile acid concentration were significantly 
elevated in experimental rats in 14 days than in 7 days compared with the control 
group.  Bile flow was reduced by 33% in 5 mg·kg-1·day-1 (7days and 14 days) 
groups but not in 1 mg·kg-1·day-1 (14 days) group.  Additionally, an inverse 
correlation between hepatic aluminum and bile flow but not serum bile acid 
concentration was found.  They concluded that aluminum exposure in rats may be 
associated with pathogenesis of parenteral nutrition-induced hepatobiliary 
dysfunction (Klein et al., 1988).  Demircan et al. (1999) investigated the effects of 
administration of PN and aluminum in rats.  Their experimental group received PN 
and/or aluminum.  The level of aluminum in PN solutions and intravenous 
aluminum dose used in this study were equal to 66.85 µg·kg-1·day-1.  The control 
group received intraperitoneal saline.  The experiment lasted for 7 to 14 days.  
Portal inflammation and hepatic aluminum accumulation was found in all 
experimental subjects.  A dose related elevation in the levels of serum bile acids 
was present (Demircan et al., 1999).  A recent study demonstrated that a chronic 
aluminum exposure damaged the biliary secretory function in rats.  The 
experimental group received aluminum intraperitoneally at 27 mg·kg-1, three times a 
week for 90 days.  The results showed that cholestasis had developed.  The ability 
of hepatic transport of organic anions was impaired by decreasing both sinusoidal 
uptake and canalicular excretion (Gonzalez et al., 2004).  Duerksen et al. (1996) 
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studied PN-induced liver disease in the newborn piglet.  For three weeks, eight 
piglets received PN and nine piglets were fed sow’s milk.  They found that liver 
and serum bilirubin were elevated in the PN group.  Bile flow was significantly 
reduced and bile composition was altered in the PN group.  They suggested that 
PNAC may be characterized by decreased bile acid secretion, elevated serum 
bilirubin and reduced bile flow (Duerksen et al., 1996).  However, the 
contamination level of aluminum of PN solutions in this study was unknown.  The 
following table is a summary of previous animal studies (Table 2.5). 
Although previous reports suggested an association with aluminum and 
PNAC, the exact role of aluminum in PNAC is still unclear.  The sample sizes of 
most human studies are small.  The experimental models used to explore the role of 
aluminum in PNAC tended to be in older animals and with aluminum dose much 
larger than the contamination levels seen today.  Considering that significant 
aluminum contamination exists, and the high risk of PNAC in infants, the proposed 
relationship requires further study. 
2.5 Piglet as a model in human neonatal research 
The use of piglets as an animal model in human neonatal research has been 
steadily increasing over the last few decades.  This increased interest in piglets as 
an animal model for human diseases has been based mainly on the similarities 
between the two species.  The neonatal piglet is considered an appropriate model 
for the human infants because of the comparative anatomy, physiology and 
metabolism (Benevenga et al., 1986; Moughan et al., 1992).  As a result, neonatal 
piglets are used as general surgical models of most organs and systems, for  
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Table 2.5  Previous animal studies on aluminum and/or TPN in PNAC 
Studies Animal Factor Dose Duration Result 
Klein et al. 
1987 
piglets, 
6 weeks old 
aluminum 1.5 mg·kg-1·day-1 50 days Cholestasis 
Duerkse et al.  
1996 
newborn  
piglets 
TPN unknown 21days Decrease bile flow and elevated 
serum total bilirubin concentration
Demircan et al. 
1998 
rats aluminum 
and/or TPN 
66.85 µg·kg-1·day-1 7 days 
14 days 
Portal inflammation 
Klein et al. 
1988 
rats aluminum 1 mg·kg-1·day-1 
5 mg·kg-1·day-1 
7 days 
14 days 
Hepatobiliary dysfunction 
Gonzalez et al. 
2004 
rats aluminum 27 mg·kg-1, 3 times a 
week 
90 days Cholestasis  
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cardiovascular research, for digestive system models, and in recent years in 
transplantation and xenografic research.  In the nutrition research area, the neonatal 
piglets has been widely used as a model for studying nutrient requirements (Reeds 
and Odle, 1996; Jahoor et al., 1999) and digestive function in human infants 
(Donovan et al., 1996), and are also used to monitor amino acid metabolism and 
gastrointestinal function during total parenteral nutrition (TPN) (Wykes et al., 1993; 
Ball et al., 1996) as well as the hepatotoxicity of TPN (Cohen et al., 1990; Duerksen 
et al., 1996).  They also have been used as a replacement for rats, or other 
experimental animals in some research.  Not only the regulatory pressure on other 
large animal species, but also because piglets are recognized as a suitable animal 
model for human diseases, the rise in using piglets in human neonatal research will 
probably continue. 
2.5.1 The similarities of porcine and human infants 
Many anatomical and physiological similarities between humans and pigs 
have been documented (Pond and Mersmann, 2001).  The predominant porcine 
systems studied in biomedical research are cardiovascular, digestive, dermal and 
urinary. 
Swine are true omnivores.  The general architecture of the gastrointestinal 
tracts of the pig and human is similar.  Notable differences are the higher proportion 
of cardiac mucosa lining the stomach of the pig, as compared with the human (Yen, 
2001), and the presence of a cecum in the pig, as compared with only a vestige, the 
appendix, in the human.  The muscular layers of the esophagus are mainly 
composed of smooth muscle until its termination cranial to the esophageal sphincter 
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when it becomes partially striated muscle.  The stomach is typical of monogastric 
animals with the exception of the torus pyloricus, which is a muscular outpouching 
near the pyloric sphincter.  The small intestine is long and located mainly in the 
right side of the abdomen.  The majority of the large intestine is located in the spiral 
colon in the left upper quadrant of the abdomen.  It consists of the cecum, ascending, 
transverse and a portion of the descending colon coiled tightly into a series of 
centripetal and centrifugal coils.  The liver contains six lobes and a gall bladder.  
The common bile duct enters the duodenum separately from the pancreatic duct 
caudal to the pylorus.  The pancreas is extensive and the tail follows the lesser 
curvature of the stomach from the spleen to the proximal duodenum.  The 
pancreatic ducts in the tail and body join at the juncture of the two lobes to enter the 
duodenum distal from the bile duct.  Functionally both the liver and pancreas are 
similar to human (Ford et al. 2001; Schantz et al., 1996). 
Early postnatal growth of the pig is characterized by a period of rapid growth.  
During the first week after birth, a well-fed pig can double its birth weight.  At birth 
the body of the pig contains only minimal amounts of fat (usually considered to be 
no more than 2% of body weight); however, the rapid growth is accompanied by a 
dramatic increase in fat deposition, and within 1 week the fat content can increase by 
10 to 20-fold.  Since the baby pig has limited capacity for fatty acid synthesis, most 
of this fat is deposited from the dietary source of preformed, long chain fatty acids.  
The relative rates of protein deposition and lean growth are very high (Wood and 
Groves, 1965).  The growth and changes in body composition in pigs that occur 
between birth and weaning at age 4 weeks are summarized in Figure 2.4 (Manners 
and McCrea, 1963; Mitchell et al., 2001). 
Compared with the human being, the piglets develop and grow more rapidly  
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Figure 2.4  Growth and body composition of the pig from birth to age 4 weeks 
(Manners and McCrea, 1963; Mitchell et al., 2001) 
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than the human infant, but this can be viewed as an accelerated model of postnatal  
growth and development (Mount and Ingram, 1971).  This rapid growth may 
heighten the piglet’s sensitivity for the detection of metabolic responses to different 
changes in the body (Wykes et al., 1993).  The newborn piglet contains <2% body 
fat, in contrast to the full-term human infant with an average fat content of 10%.  
The newborn piglets resemble the low-birth-weight human infant in fat content.  
Therefore, the piglet is increasingly used as a model for studies of alimentation of 
premature infants, especially in lipid metabolism. 
2.5.2 The comparison of piglet model and human infants in parenteral 
nutrition associated cholestasis 
Parenteral nutrition is very important for human infants who cannot tolerate 
enteral feeding.  The piglet and humans have nearly identical gastrointestinal, 
hepatic, and hemopoietic physiology.  Nutrient requirements, growth rates and 
dentition are also comparable (Burrin, 2001) (Table 2.6). 
For these reasons, more and more researches choose the neonatal piglets as 
the animal model for human neonatal research in PN therapy.  Cohen et al. (1986) 
placed 53 piglets with a mean weight of 1.8 kg and a mean age of 3.1 days on TPN 
for periods ranging from 6 to 31 days.  Clinical complications were similar to those 
observed in human infants on PN therapy.  It has been possible to maintain piglets 
with a central venous catheter for significant periods of time (up to 50 days) safely 
and effectively (Klein et al., 1987).  In recent studies, piglets are used as the animal 
model in evaluating the nutrients in parenteral feeding formula, contaminators in PN 
solution and the complications of PN therapy in infants (Van-Aerde et al., 1999; 
Bertolo et al., 1999; Duerksen et al., 1996; Dahlke et al., 2004). 
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Table 2.6  Comparison of nutrient requirements of the human infant and the 
piglet 
 
Nutrient Piglet 
Requirement1 
(unit·kg-1·d-1) 
Human infant 
Requirement2  
(unit·kg-1·d-1) 
Ratio 
piglet: human infant 
Energy (kcal) 205 108 1.9 
Protein (g) 16.25 1.52 10.7 
Sodium (mg) 158 ND3 ND3 
Calcium (mg) 563 35 16.1 
Phosphorus (mg) 438 16.7 26.2 
Chlorine (mg) 158 20.8 7.6 
Magnesium (µg) 250 5000 0.05 
Potassium (mg) 188 ND3 ND3 
Copper (mg) 0.375 0.033 11.4 
Iodine (µg) 10 18.3 0.6 
Iron (mg) 6.25 0.045 138.9 
Manganese (µg) 250 0.5 500 
Selenium (µg) 20 2.5 8 
Zinc (mg) 6.25 0.33 18.9 
Vitamin A (µg) 41.3 66.7 0.6 
Vitamin D (µg) 0.34 0.83 0.4 
Vitamin E (µg) 0.67 0.67 1 
Vitamin K (µg) 32.5 0.33 98.5 
Vitamin C (mg) ND3 6.67 ND3 
Biotin (µg) 5 0.83 6 
Choline (mg) 37.5 20.8 1.8 
Folate (µg) 20 10.8 1.9 
Niacin (mg) 1.25 0.33 3.8 
Pantothenic acid (µg) 750 283 2.7 
Riboflavin (µg) 250 50 5 
Thiamin (µg) 95 33.3 2.9 
Vitamin B6 (µg) 125 16.7 7.5 
Vitamin B12 (µg) 1.25 0.067 18.7 
Linoleic acid (mg) 62.5 0.73 85.6 
1. Calculated from nutrients requirement for 3-5 kg piglets (NRC, 1998). 
2. Calculated from nutrients requirement for 0-6 months infant (National 
Academy of Sciences, 2002). 
3. Not determined. 
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In liver diseases research, because of the similarities of the anatomy and 
physiology of liver and bile secretion, piglet also is used as an animal model to 
represent the hepatobiliary function in the human infants.  A comparative study of 
the hepatic bile ducts of human and laboratory animals was made by means of 
scanning electron microscopy of biliary tract casts (Yamamoto et al., 1985).  In the 
pig, many pouches are observed around not only large but also small bile ducts, 
which is similar to the human being.  No such structures are observed in dog, 
guinea pig, or rabbit bile ducts.  Many suitable piglet models are developed to 
demonstrate the different characteristics of liver function in human infants (Desport 
et al., 1997; Truskett et al., 1987; Dahlke et al., 2004). 
For the reasons stated, the piglet model is suitable and useful for studying 
PNAC in infants.  Development of suitable models in piglets could be valuable in 
the understanding and prevention of PNAC in human infants.
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3. EXPERIMENTS 
3.1 The role of aluminum in parenteral nutrition associated cholestasis in 
human infants: a prospective study 
3.1.1 Introduction 
Aluminum is a known contaminant of PN solutions (Klein, 2003).  Elevated 
aluminum level in urine, blood, liver, bone and brain has been documented in 
patients on PN (Sedman et al., 1985; Koo et al., 1986; Moreno et al., 1994).  
Despite attempts by several investigators, the role of aluminum in PNAC remains 
obscure.  The safe aluminum levels for the infants on PN are not established (Klein, 
2003).  Some questions concerning aluminum exposure, the prematurity of the 
infants, and the whole process of developing PNAC need to be defined.   
The study was designed to investigate the relationship between the serum 
aluminum levels and the direct bilirubin concentrations in gastrointestinal failure 
infants who required PN.  The hypothesis of the study is the increased serum 
aluminum concentration would be correlated with increased serum direct bilirubin in 
PNAC infants.  Other potential factors may also play roles in this relationship. 
3.1.2 Methods 
3.1.2.1 Subjects 
Patients were recruited from the neonatal intensive care unit (NICU) at the 
Royal University Hospital (RUH), Saskatoon, Saskatchewan, Canada.  Eligible 
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patients were infants, age <365 days who meet inclusion criteria of anticipating to 
require PN therapy for 3 weeks secondary to the diagnosis of gastrointestinal failure.  
Patients were excluded if they were diagnosed with the following diseases: 
1. congenital hepatic or biliary disorder such as: extrinsic obstruction of the biliary 
system, hepatic neoplasm, inspissated bile syndrome, spontaneous perforation of 
the common bile duct, infantile obstructive cholangiopathy (neonatal hepatitis, 
biliary atresia, biliary hypoplasia, choledochal cyst, Alagille’s syndrome) 
2. major cardiac anomaly 
3. other congenital or acquired disorders which may cause hepatic disease such as: 
hepatitis, syphilis, rubella, toxoplasmosis, metabolic disorders (i.e., 
galactosaemia, fructosaemia, alpha-1-antitrypsin deficiency, cystic fibrosis) and 
endocrine disorders (i.e., hypothyroidism, hypopituitarism, hypoadrenalism) 
All subjects enrolled received the pediatric PN solutions (see the 
components of PN solutions in Table 3.2 in the results) made by the Department of 
Pharmaceutical Service in the RUH.  From a review of health records, we have 
identified infants with intestinal failure from necrotizing enterocolitis, gastroschisis, 
omphalocele, intestinal atresia, and intestinal aganglionosis as likely to require PN 
for at least 3 weeks.   
3.1.2.2 Design 
Patients were enrolled by a research team in NICU at the RUH.  Eligible 
patients were followed during the PN therapy.  The anticipated period for the study 
was 3 weeks.  During the study period, blood samples were taken from the patients 
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once a week and analyzed for the aluminum levels, liver enzymes, and bilirubin.  
The diagnosis of PNAC was made when the serum direct bilirubin was greater than 
34 μmol·L-1 during the PN therapy (Moreno et al., 1994; Hata et al., 1993; Beath et 
al., 1996; Kubota et al., 2000; Teitelbaum et al., 2001).  The research protocol, 
including the consent process and form has been approved by the University of 
Saskatchewan Advisory Committee on Ethics in Human Experimentation and the 
Saskatoon District Health Ethics Committee (Appendix A).  Informed consent for 
participation in the study will be obtained from the subject’s legal guardian.  See 
appendices for the study protocol (Appendix B) and consent form (Appendix A). 
3.1.3 Sample collection and analysis 
Eligible patients’ basic information and PN solution intake were obtained 
from their hospital records.  Daily weights were recorded by the nurse in the NICU.  
At day 0, day 7, day 14 and day 21, 5 mL blood was collected in the metal free tubes 
from each enrolled patient by phlebotomy personnel at the Royal University Hospital.  
The serum was analyzed for serum biochemistry including alkaline phosphatase 
(ALP), gamma glutamyl transferase (GGT) and bilirubin (direct and indirect 
bilirubin) as well as aluminum evaluation.  Serum biochemistry was determined on 
a Beckman-Coulter LX-20 by standard enzymatic methods (Fody E.P., 2000) at the 
Department of Laboratory Medicine in RUH.  Aluminum level was determined at 
the Saskatchewan Research Council (SRC), Saskatoon, Canada, by inductively 
coupled plasma atomic emission spectrometry (ICP-AES).  See Appendix D for the 
quality control of aluminum analysis. 
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3.1.4 Statistical methods 
Descriptive statistics was performed on the raw data.  Results are expressed 
as mean ± standard deviation (SD).  Two-tailed Pearson correlation is performed to 
test the relationship of serum aluminum and serum bilirubin.  PNAC patients are 
compared with non-PNAC patients by unpaired t-tests.  Values are considered 
significant at p<0.05. 
3.1.5 Results 
3.1.5.1 General  
A total of sixteen patients were enrolled (Table 3.1).  There were ten males 
and six females in the study.  These patients were diagnosed with intestinal atresia 
(n=8), gastroschisis (n=7) and meconium peritonitis (n=1).  The birth weight was 
2426±795 g (900g to 3627 g).  The average gestation age was 35.4±4.0 weeks (26 
to 42 weeks).  The duration of PN therapy was 16.2±7.9 days (7 to 35 days).  
Aluminum content in each component of the PN solution was measured.  
The aluminum concentration, based on the standard hospital formulation for infants 
was calculated at 252.6 μg·L-1 (Table 3.2).  The volume of fluids intake was 
obtained from the hospital records, and the mean daily aluminum received from PN 
in these infants was estimated at 21.6±5.2 μg·kg-1·day-1 (Table 3.3).  
3.1.5.2  PNAC group versus non-PNAC group 
Five of sixteen (31.3%) patients developed PNAC, which was diagnosed 
when serum direct bilirubin was greater than 34 μmol·L-1.  There were no 
significant differences between the PNAC and non-PNAC group in birth weight,  
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Table 3.1  The gender, birth weight, gestation age, duration of PN and 
diagnosis of the enrolled infants 
 
Subject 
number 
Gender 
Birth 
weight (g) 
Gestation 
age (weeks) 
Duration 
of PN 
(days) 
Diagnosis 
PNAC subject 
number 
     
1 male 1510 31 19 Intestinal atresia 
3 male 1670 32 12 Intestinal atresia 
4 male 2380 35 12 Gastroschisis 
11 male 2290 36 21 Intestinal atresia 
15 male 3120 38 16 Meconium peritonitis 
PNAC 
Subtotal (n=5) 
male 
(n=5) 
female 
(n=0) 
2194±641 34.4±2.9 16.3±4.1 
Intestinal atresia (n=3) 
Gastroschisis (n=1) 
Meconium peritonitis (n=1) 
Non-PNAC 
subject number 
     
2 male 3627 40 7 Intestinal atresia 
5 female 3050 36 10 Gastroschisis 
6 female 3030 38 15 Gastroschisis 
7 female 2720 37 14 Gastroschisis 
8 female 2540 38 9 Intestinal atresia 
9 female 1700 33 10 Intestinal atresia 
10 female 2470 35 25 Gastroschisis 
12 male 900 26 35 Intestinal atresia 
13 male 3300 42 13 Intestinal atresia 
14 male 3150 39 11 Gastroschisis 
16 male 1360 31 30 Gastroschisis 
Non-PNAC 
Subtotal 
(n=11) 
male 
(n=5) 
female 
(n=6) 
2531±863 35.9±4.5 16.0±9.4 
Intestinal atresia (n=5) 
Gastroschisis (n=6) 
Total (n=16) 
male 
(n=10) 
female 
(n=6) 
2426±795 35.4±4.0 16.2±7.9
Intestinal atresia (n=8) 
Gastroschisis (n=7) 
Meconium peritonitis (n=1) 
1. Data of birth weight, gestation age and duration of PN in subtotal and total were 
expressed as mean ± SD. 
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Table 3.2  Aluminum concentrations in parenteral solutions used in the 
hospital 
Product Aluminum 
concentration (μg·L-1) 
Pediatric PN 
solution11 (mL·L-1) 
Aluminum13 
(μg) 
Pediatric amino acid 10%1  
(Aminosyn PF) 
<5012 250 6.3 
Sterile water2 2.2 557 1.2 
Dextrose 70%3 <5012 125 3.1 
Potassium phosphate4 7900 3 23.7 
Potassium acetate5 <5012 0.3 0.0 
Calcium gluconate6  4200 51.6 216.7 
Zinc sulfate7 400 2.13 0.9 
Sodium chloride 23.4%8 <10012 2.8 0.1 
Sodium acetate9 60 7.5 0.5 
Magnesium sulfate 50%10 <30012 0.72 0.1 
Total   1000 252.6 
1. One mL contains 100 mg amino acids.  Baxter Corporation, Mississauga, Ontario, Canada. 
2. Baxter Corporation, Mississauga, Ontario, Canada. 
3. One mL contains 700 mg dextrose.  Baxter Corporation, Mississauga, Ontario, Canada. 
4. One mL contains 224 mg potassium phosphate monobasic, and 236mg potassium phosphate 
dibasic.  Pharmaceutical Partners of Canada Inc., Richmond Hill, Ontario, Canada. 
5. One mL contains 196.28 mg potassium acetate.  Pharmaceutical Partners of Canada Inc., 
Richmond Hill, Ontario, Canada. 
6. One mL contains 94 mg calcium gluconate, 4.5mg calcium saccarate.  Pharmaceutical 
Partners of Canada Inc., Richmond Hill, Ontario, Canada. 
7. One mL contains 21.95 mg zinc sulfate.  Sabex 2002 Inc., Boucherville, Quebec, Canada. 
8. One mL contains 234 mg sodium chloride.  Sabex 2002 Inc., Boucherville, Quebec, 
Canada. 
9. One mL contains 164 mg sodium acetate.  Pharmaceutical Partners of Canada Inc., 
Richmond Hill, Ontario, Canada. 
10. One mL contains 500 mg magnesium sulfate.  Pharmaceutical Partners of Canada Inc., 
Richmond Hill, Ontario, Canada. 
11. The formula was obtained from the Department of Pharmaceutical Service in RUH. 
12. When the concentration was under the detected limitation, half of the value was used in the 
calculation. 
13. The calculation of aluminum is: Aluminum concentration (μg·L-1) X Pediatric PN solution 
(mL·L-1) / 1000 = Aluminum (μg). 
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Table 3.3  An example of the calculation of parenteral aluminum intake from 
the PN therapy1 
 
PN therapy Aluminum 
concentration 
(μg·L-1) 
Intake during 
PN therapy 
(mL·kg-1·day-1) 
Parenteral 
aluminum intake7 
(μg·kg-1·day-1) 
Pediatric PN solutions 252.65 85.9 21.7
Intralipid 20%2 1006 11.9 1.2
Pediatric multivitamins3 2206 2 0.4
Pediatric trace elements4 3506 0.05 0
Total  23.3
1. The mean of intake (mL·kg-1·day-1) was calculated from the hospital records. 
Data in this table were from one of the enrolled infants (subject number 8) 
2. One mL contains 20 mg lipids.  Fresenius Kabi AB, Uppsala, Sweden. 
3. One mL contains 460 IU vitamin A, 16 mg vitamin C, 80 IU vitamin D, 0.24 mg 
thiamine, 0.28 mg riboflavin, 0.2 mg pyridoxine, 3.4 mg niacinamide, 1.0 mg 
pantothenic acid, 1.4 IU vitamin A, 4 μg biotin, 28 μg folate, 0.2 μg vitamin B12, 
and 40 μg vitamin K.  Sabex 2002 Inc., Boucherville, Quebec, Canada. 
4. One mL contains 3.0 mg zinc, 0.1 mg manganese, 0.4 mg copper, 4.0 μg 
chromium, 20 μg selenium, and 60 μg iodine.  Sabex 2002 Inc., Boucherville, 
Quebec, Canada. 
5. The value is from the total aluminum in the PN solution in Table 3.2 
6. The concentrations of aluminum were determined at Saskatchewan Research 
Council (SRC), Saskatoon. 
7. The calculation of parenteral aluminum intake is: Aluminum concentration 
(μg·L-1) X Intake during PN therapy (mL·kg-1·day-1) = Parenteral aluminum 
intake (μg·kg-1·day-1). 
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gestation age, and duration of PN therapy.   
The mean serum ALP and GGT for both groups remained in the normal range 
throughout the study (Figure 3.1, Figure 3.2).  The mean serum total bilirubin 
peaked at day 7 in both PNAC infants and non-PNAC infants (Figure 3.3).  There 
were no significant differences between these two groups in the mean serum total 
bilirubin on day 0, day 7, day 14 and day 21. 
Thirteen of sixteen infants in the study developed direct hyperbilirubinemia. 
Five infants developed PNAC based on a serum direct bilirubin ≥ 34 μmol·L-1.  
Both the PNAC and non-PNAC groups had similar serum direct bilirubin 
concentrations at the baseline.  However, the PNAC group demonstrated a linear 
increase (r2=0.481, p<0.01) while the non-PNAC group’s values did not increase 
during the experiment (Figure 3.4).   
The mean parenteral aluminum intake of both groups demonstrated a similar 
trend, starting with the greatest value at the baseline with steady decline over time 
(Figure 3.5).  The similar trend of the mean serum aluminum concentration was 
shown in both the PNAC and non-PNAC infants (Figure 3.6).  The concentrations 
peaked at day 7 and then declined thereafter.  There were no significant differences 
between two groups in serum aluminum concentrations at day 0, day 7, day 14 and 
day 21.  There was no significant correlation between the serum direct bilirubin 
concentrations and the serum aluminum levels in these infants (p>0.05). 
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Figure 3.1  Serum ALP in the PNAC infants versus non-PNAC infants 
The symbols (■ and ♦) represent means.  Error bars are SD.  n=8 for non-PNAC 
group at day 14.  n=3 for PNAC group and n=6 for non-PNAC group at day 21.  
The reference value of serum ALP is from 150 to 500 U·L-1. 
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Figure 3.2  Serum GGT in PNAC infants versus non-PNAC infants 
The symbols (■ and ♦) represent means.  Error bars are SD.  n=8 for non-PNAC 
group at day 14.  n=3 for PNAC group and n=6 for non-PNAC group at day 21.  
The reference value of serum GGT is from 20 to 200 U·L-1. 
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Figure 3.3  Serum total bilirubin in PNAC infants versus non-PNAC infants 
The symbols (■ and ♦) represent means.  Error bars are SD.  n=8 for non-PNAC 
group at day 14.  n=3 for PNAC group and n=6 for non-PNAC group at day 21.  
The reference value for serum total bilirubin is from 2 to 22 μmol·L-1. 
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Figure 3.4  Serum direct bilirubin in the PNAC infants versus the non-PNAC 
infants 
The symbols (■ and ♦) represent means.  Error bars are SD.  n=8 for non-PNAC 
group at day 14.  n=3 for PNAC group and n=6 for non-PNAC group at day 21.  A 
linear trend is shown in PNAC group (r2=0.481, p<0.01).  The reference value for 
serum dirct bilirubin is from 0 to 5 μmol·L-1. 
  57
0
5
10
15
20
25
week1 week2 week3
weeks
A
l p
ar
en
te
ra
l i
nt
ak
e
(u
g/
kg
/d
ay
)
PNAC
non-PNAC
 
Figure 3.5  The mean parenteral aluminum intake in the PNAC group versus 
the non-PNAC group 
The symbols (■ and ♦) represent means.  The calculation of parenteral aluminum intake was demonstrated in Table 3.3.  n=5 
(PNAC group) and n=11 (non-PNAC group) for week1.  n=5 (PNAC group) and n=8 (non-PNAC group) for week2.  n=3 
(PNAC group) and n=6 (non-PNAC group) for week3. 
 
0
200
400
600
800
1000
1200
0 7 14 21
days
se
ru
m
 a
lu
m
in
um
 c
on
ce
nt
ra
tio
(u
g/
L
)
PNAC (n=5)
non-PNAC (n=11)
 
Figure 3.6  Serum aluminum concentrations in the PNAC infants versus the 
non-PNAC infants 
The symbols (■ and ♦) represent means.  Error bars are SD.  When the 
concentration was under the detected limitation, half of the value was used in the 
calculation.  n=8 for non-PNAC group at day 14.  n=3 for PNAC group and n=6 
for non-PNAC group at day 21. 
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3.1.6 Discussion 
The incidence of PNAC was 31.25% (5 of 16).  In our unpublished 
retrospective data (Arnold, 2004) the incident rate of PNAC was 25%, which was in 
agreement with Kubota’s work (Kubota et al., 2000).  The variation in reported 
incidence is due to differences in study populations, diagnosis of cholestasis, 
duration of the study time, and other medical or surgical conditions in the study 
subjects (Btaiche and Khalidi, 2002).  
There was no statistical difference in birth weight between the PNAC and 
non-PNAC infants.  Previous human studies suggested that PNAC was more 
common in extremely low birth weight infants (Beale, et al., 1979; Drongowski and 
Coran, 1989; Kelly, 1998).  In Beale’s work, the infants with birth weight under 
1000 g had an incidence of 50% (Beale et al., 1979).  In our unpublished 
retrospective study, results showed that birth weight less than 1600 g significantly 
contributed to the development of PNAC (Arnold, 2004).  It is important to point 
out only one infant had a birth weight under 1000 g, and three had a birth weight less 
than 1600 g in this prospective study.  The reason this study did not show a 
significant difference may be due to the small size of the sample.  Other human 
studies also showed mixed results regarding the role of birth weight in PNAC.  
There is no agreement on the cut-off line for low birth weight infants who may have 
a high risk for PNAC (Beale, et al., 1979; Drongowski and Coran, 1989; Kelly, 1998).  
Gestation age is also related to birth weight.  Note that only one infant in the study 
had a gestation age lower than 30 weeks.  Our unpublished retrospective study 
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suggested that PNAC infants were born at relatively the same gestation age yet were 
significantly lighter (Arnold, 2004).  This may explain the no difference showed in 
gestational age between the PNAC group and the non-PNAC group.  Both birth 
weight and gestation ages are markers of maturity of infants at birth.  Most of the 
investigators agreed that the premature infants were on the high risk of PNAC 
(Btaiche and Khalidi, 2002; Beath et al., 1996).  However, when birth weight or 
gestation age were used as the markers of prematurity, mixed results were found in 
the previous human studies (Baserga and Sola, 2004; Zambrano et al., 2004; 
Drongowski and Coran, 1989). 
The duration of PN is another potential factor of PNAC development in 
infants (Gremse and Balistreri, 1989).  No significant difference was found in 
duration of PN in the study.  This agreed with Beath’s work, which suggested that 
the duration of PN did not correlate significantly with the development of cholestasis 
(Beath et al., 1996).  However, it is important to note that the small number of the 
patients in our study may affect the difference between PNAC and non-PNAC 
infants.  Moreover, the experimental period was only 3 weeks.  It may be different 
in the patients who required long term PN therapy. 
Serum ALP and GGT are used as indicators of cholestastic disease.  Both 
serum ALP and GGT were within the normal range.  However, serum direct 
bilirubin had already increased, which indicated the development of PNAC.  
Therefore, serum ALP and GGT may not be a sensitive indicator for PNAC.  
The mean total bilirubin and direct bilirubin concentrations in the study are 
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clinically different.  The mean total bilirubin of all 16 infants demonstrated a steady 
increase from baseline peaking on day 7 and then a steady decline approaching 
normal.  The mean indirect bilirubin had the similar trend as the mean total bilirubin.  
This trend was considered as physiological jaundice of the newborn (Hansen, 2000).  
For the mean direct bilirubin, the PNAC group demonstrated a linear increase while 
non-PNAC group’s values did not increase while on PN.  Since there were no 
significant difference in birth weight, gestation age and the duration of PN between 
these two groups, other factors would be responsible for the significant difference in 
the mean direct bilirubin.  Serum direct bilirubin was the indicator and diagnosis 
standard for PNAC.  PNAC was diagnosed when the serum direct bilirubin was 
greater than 34 μmol·L-1, which was much higher than the normal value (0 to 5 
μmol·L-1).  The diagnosis standard was adapted from the previous human studies 
(Moreno et al., 1994; Hata et al., 1993; Beath et al., 1996).  However, the diagnostic 
standard for PNAC used in the study was relatively arbitrary.  It was interesting to 
find that there was 9 infants developed PNAC if the diagnosis standard for PNAC 
was the serum direct bilirubin greater than 12 μmol·L-1.  Moreover, these PNAC 
infants (n=9) would have a significant lower birth weight (p<0.01) and gestation age 
(p<0.01) compared with the non-PNAC infants (n=7).  Note that thirteen of sixteen 
infants developed conjugated hyperbilirubinemia during the PN therapy.  
Conjugated hyperbilirubinemia occurs when bilirubin is returned to the bloodstream 
after conjugation in the liver, instead of draining into the bile ducts.  The most 
common causes are hepatocellular disease, intrahepatic cholestasis and extrahepatic 
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obstruction (Hansen, 2000).  The hepatobiliary dysfunction is one of the most 
common complications of PN therapy. 
For infants who receive PN, the major source, and in many cases the only 
source of aluminum intake is the contaminant aluminum in PN solutions (Moreno et 
al., 1994).  Different products, even different lot numbers may also contain the 
different contamination levels of aluminum in PN solutions (Klein, 2003).  The 
amount of aluminum in PN solutions may vary from different reports.  In Moreno’s 
study, the Al contamination level was about 10.6 to16.7 μg·kg-1·day-1 for the infants 
on PN (Moreno et al., 1994).  Another study in Alberta, Canada showed that the 
level ranged from 17.9 to 38.3 μg·kg-1·day-1 for the neonatal patients on PN (Koo et 
al., 1986).  The mean parenteral intake of aluminum in the total 16 patients was 
21.6 μg·kg-1·day-1.  Similar parenteral aluminum intake was found in both PNAC 
and non-PNAC infants.  It is important to note that this aluminum level in PN 
solutions significantly exceeds the 2 μg·kg-1·day-1 safe level that is recommended for 
adult (ASCN/ASPEN, 1991).  The declined level of parenteral aluminum intake in 
the third week (Figure 3.5) was because most of the subjects decreased the intake 
from the PN solutions and started the oral intake in the third week of the study.    
Serum aluminum peaked on day 7 and then declined after in both the PNAC 
and non-PNAC group.  This fall after 7days may be due to further maturity of the 
renal system in these patients, which thus increases the elimination of aluminum.   
The parenteral aluminum intake was not correlated with serum aluminum levels.  
The variability of excretion and deposition would explain why these infants had the 
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same aluminum intake but different serum aluminum levels.  Although full-term 
infants have better renal function than premature newborns, they also have a reduced 
glomerular filtration rate compared with adults and do not reach normal values until 
1-2 years of age (Engle, 1986).  Thus, with the unsafe level of parenteral aluminum 
intake, combined with low aluminum excretion ability or high aluminum deposition 
in the liver may put the infants who required PN at a high risk of PNAC.  In the 
United Sates, legislation was made by the Food and Drug Administration to limit the 
amount of aluminum allowable in intravenous solutions (FDA, 2000). 
There was no positive relationship between serum aluminum and serum direct 
bilirubin.  Serum aluminum is not a good marker of PNAC.  The peak of serum 
aluminum was at day 7 although the serum direct bilirubin kept climbing up to day 
21 in the PNAC infants.  The result may be due to the accumulation of aluminum in 
the liver and further damage the ability to excrete aluminum.  In the previous 
human studies, elevated serum aluminum levels were found in the PNAC infants 
(Moreno et al., 1994; Koo et al., 1986).  However, there has never been any proven 
relationship between serum aluminum and degree of cholestasis in humans (Klein, 
2003).  
One limitation of this research is that the medications that could cause 
cholestasis were not accounted for, such as anabolic steroids, chlorpromazine, 
prochlorperazine, sulindac, cimetidine, ampicillin, and other penicillin-based 
antibiotics.  However, most of these drugs are rarely used in the neonatal patients.  
For parenteral aluminum intake, there may be variation from batch to batch in PN 
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solutions.  It was not practical and worthwhile to check the aluminum level of every 
bag.  The estimated aluminum level in the study is close to other reports which may 
use similar products ( Koo et al., 1986; Moreno et al., 1994; Klein, 2003).  
Although the intravenous drugs may also contribute to the aluminum level, they only 
represent 1.7% of total parenteral aluminum intake (Moreno et al., 1994).  
Therefore, the aluminum in PN solution may be responsible for the aluminum 
loading of the infants.  The major aluminum contributor in PN solution was 
electrolytes (see Table 3.2).  The different concentrations of electrolytes other than 
the formulation may be used in the PN solution for the individual patients.  Thus, 
the different aluminum concentrations in the PN solutions for different patients 
weren’t accounted for.  Serum aluminum level could only reflect aluminum 
exposure.  The elimination of aluminum was not assessed.  Moreover the small 
sample size of this study may hinder statistical comparison between the PNAC and 
non-PNAC group.  
3.1.7 Conclusion 
PNAC has been shown to develop in less than three weeks in the infants with 
gastrointestinal failure who required PN therapy.  Despite the similar parenteral 
aluminum intake, PNAC (serum direct bilirubin level ≥ 34 μmol·L-1) only occured in 
5 patients.  Serum aluminum level had a peak on day7 then declined thereafter, and 
it was not directly correlated with parenteral aluminum intake or serum direct 
bilirubin.  
It has been suggested that the cause of PNAC in infants are multifactorial 
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(Balistreri et al., 1983; Merrit, 1986; Klein, 2003).  The variability of each potential 
factor that contributes to the disease in individual infants is high.  The significant 
exposure to aluminum in the infants who required PN therapy can cause its 
accumulation in organs leading to toxicity.  The aluminum contaminant in PN 
solutions has been implicated as one of the potential factors in the development of 
PNAC.  However, the mechanism of aluminum in the etiology of PNAC is still 
unclear.  And the contribution of aluminum in this multifactor model and the 
relationship with other potential factors requires further exploration. 
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3.2 The role of aluminum in parenteral nutrition associated cholestasis in 
neonatal piglets: an experimental model study 
3.2.1 Introduction 
Human infant study is constrained by several factors, including: a 
heterogeneous population, ethical and practical limitations, and acceptable methods 
design.  Therefore, the application of an animal model permits experimental study 
which can provide a comprehensive and in-depth picture of the role of aluminum in 
the development of PNAC.  Several studies have shown that aluminum 
administered to rats and piglets in experimental pharmacologic doses produces 
cholestasis (Klein et al., 1988; Klein et al., 1987; Dermircan et al., 1998; Gonzalez et 
al., 2004).  However, previous animal experiments used non-neonatal animals with 
aluminum doses far exceeding the level of contamination seen in the human patient 
care today.   
A neonatal piglet model that used the same level of aluminum contamination 
as found in the hospital and imitated the infants on PN therapy was developed in this 
study.  Techniques for central venous catheterization, sampling blood, patency of 
catheter, PN regimen delivery, and aluminum infusion were developed to facilitate 
the experiment.  The overall objectives of the study were to compare different doses 
of intravenous aluminum in the development of cholestasis and to determine if PN 
therapy with contaminant aluminum is associated with the development of PNAC.  
Experimental procedures were approved by the University of Saskatchewan 
Committee on Animal Care and Supply Protocol Review Committee (Appendix A). 
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3.2.2 Materials and methods 
3.2.2.1 Animals 
Neonatal piglets were selected because of the comparative anatomy, 
physiology and metabolism between human infants and neonatal piglets, especially 
the similarities of liver function and bile secretion (Pond and Mersmann, 2000).  
Furthermore, the similar clinical complications to those observed in human infants 
on PN were found in the piglets (Tumbleson, 1986).  Previous animal studies 
already demonstrated the safety and efficiency in keeping the catheter in the piglets 
up to 50 days and maintaining piglets on PN for 3 weeks (Klein et al., 1986; 
Duerksen et al., 1996). 
3.2.2.2 Design 
24 piglets, 2 to 4 days old, were obtained from the University of 
Saskatchewan Prairie Swine Center and placed into four groups: (1) Control group 
(n=5): daily intravenous injection saline (0.9% sodium chloride); (2) Low Al 
(aluminum) group (n=7): daily intravenous injection with aluminum dose at 20 
μg·kg-1·day-1; (3) High Al (aluminum) group (n=6): daily intravenous injection with 
aluminum dose at 1500 μg·kg-1·day-1; (4) PN group (n=6): continuous PN solutions 
with aluminum intake at 37.8±14.3 μg·kg-1·day-1.   
The aluminum content of saline (Abbott Laboratories, Montreal, Quebec, 
Canada) was lower than 1 μg·L-1 and has been used as control material in the 
previous aluminum studies (Klein et al., 1986; Klein et al., 1988; Demircan et al., 
1998; Gonzalez et al., 2004).  The aluminum injections in the Low Al and High Al 
groups were in the form of aluminum chloride hexahydrate (Fisher Scientific, 
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Mississauga, Ontario, Canada).  See Appendix B for the preparation of aluminum 
injection.  The aluminum level 20 μg·kg-1·day-1 in the Low dose group represents 
the contaminating level in the clinical PN therapy in infants (Moreno et al., 1994).  
The high dose aluminum 1500 μg·kg-1·day-1 was the dose used in the previous study 
for adult pigs for 50 days (Klein et al., 1986).  The PN group received a balanced 
PN solution which was designed to, as closely as possible, achieve the estimated 
intravenous nutrient requirements of the piglet.  All the solutions used in the PN 
regimen were the same commercial products used in the local hospital for infants.  
The amount of aluminum in these PN solutions was measured.  The experiment 
time was 21 days. 
3.2.2.3 Surgery 
All operations were carried out with sterile technique in a Canadian Council 
on Animal Care certified operative facility at the Medical Research Building, 
University of Saskatchewan.  The Subjects were given intramuscular (im) atropine 
(Glaxo Laboratories Inc., Toronto, Ontario, Canada) 0.09 mg·kg-1 prior to induction 
of anesthesia.  Anaesthesia was induced with Ketamine (Rogarsetic, Rogar STB 
Inc., Montreal, Quebec, Canada) 22 mg·kg-1 im and Acepromaxine (Atravet, Ayerst 
Laboratories, Montreal, Quebec, Canada) 0.5 mg·kg-1 im.  They were intubated and 
mechanically ventilated, with anesthesia maintained by isoflurane, administered 
nitrous oxide and oxygen (1:2).  Excenel (3 mg·kg-1·day-1, im) (Pharmacia Animal 
Health, Missasaga, Ontario, Canada) was administered as a preoperative prophylactic 
antibiotic. 
An incision was made on the right side of the neck and a 3 French (outside 
diameter) silicone implanted venous access catheter (Fisher Scientific, Mississauga, 
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Ontario, Canada) was inserted into the central venous system via an internal jugular 
vein and tunneled under the skin and exited on the animal’s back.  The animals 
were fitted with bandages to protect the catheter.  For the piglets in the PN group, 
the end of the catheter was attached to a metal anchor and fixed into a special jacket 
(Lomir Biomedical Inc., Perrot, Quebec, Canada).  
3.2.2.4 The care of piglets 
The piglets were housed in a room with a 12-hour light/dark cycle.  The 
room temperature was maintained at 27o Celsius.  The piglets were kept in 
individual cages with a secured feeder and water supply.  Each cage had an 
adjustably positioned heat lamp.  Excluding the PN group, the piglets had free 
access to food and water.  PN solutions were administered through a tether-swivel 
system (Lomir Biomedical Inc., Perrot, Quebec, Canada).  The swivel was secured 
at the top of the cage.  The tether was attached to the anchor on the piglet’s jacket.  
The system allowed the piglet freedom of movement without twisting or tangling the 
tubing.  Each piglet had access to a toy for entertainment, and a blanket for resting. 
All piglets were monitored daily for intake, weight gain, color of mucus 
membranes, feces and urine production.  Cages were cleaned and the blanket 
changed daily.  The patency of catheter was maintained by daily flushing with 
0.9%sodium chloride solution (Abbott Laboratories, Montreal, Quebec, Canada).  
The incisions were cleaned daily until healed and the sutures were removed on 
postoperative day 7.  
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3.2.2.5 Parenteral nutrition (PN) formulation and PN regimen delivery 
The PN formulation was designed to provide all nutrients required by the 
neonatal piglets.  The intravenous nutrient requirements were estimated from the 
requirements of orally fed piglets (NRC, 1998) and the consideration of the role of 
the gastrointestinal tract in the metabolism of each nutrient.  The estimated 
intravenous requirements are calculated in Table 3.4.  Estimated requirement 
achieved by PN was shown in Table 3.5. 
PN solutions were made everyday in a sterile lab in the College of Pharmacy 
and Nutrition, University of Saskatchewan.  The procedure of PN solution 
compounding was discussed and approved by the clinical pharmacist.  See the 
procotol of PN solution preparation in Appendix B.  The commercial products used 
were the same products used in the local hospital (Table 3.6). 
PN solutions were delivered by an infusion pump (Lifecare 5000, Abbott 
Laboratories, Chicago, USA) with pressure sensitive cassette tubing (Primary Pump 
Set, Abbott Laboratories, Montreal, Quebec, Canada).  The lipid component of the 
PN was transferred to 30 or 60 mL syringes, and infused by syringe infusion pumps 
(Sage Pump, Model 365, Orion, USA).  Rates were adjusted for daily weight gain 
to deliver 280 mL·kg-1·day-1 of PN solutions and 20 mL·kg-1·day-1 of lipids.  PN was 
started approximately 3 hours after surgery.  The rate started at 10 mL·hour-1 for PN 
solutions and 0.5 mL·hour-1 for lipids.  Rates were increased gradually, so that a 
total fluid intake of 300 mL·kg-1·day-1 was achieved by 36 hours after surgery, and 
maintained thereafter. 
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Table 3.4  Estimated intravenous nutrient requirements for the piglets  
Nutrient 
Oral 
requirement1 
(4kg·day-1) 
Oral 
requirement2 
(unit·kg-1·day-1) Bioavailability3 
Estimated intravenous 
requirement5 
(unit·kg-1·day-1) 
Metabolizable energy, kcal 820 205 1.00 205
Amino acids, g 65.0 16.3 1.00 16.3
Indispensable amino acids, g 24 6.0 1.00 6.0
Dextrose, g ND4 ND4 ND4 ND4
Sodium, mmol 27.4 6.85 0.90 6.14
Potassium, mmol 19.2 4.80 0.90 4.31
Calcium, mmol 56.1 14.0 0.50 7.0
Magnesium, mmol 4.1 1.03 0.57 0.59
Chloride, mmol 17.7 4.44 0.89 4.0
Phosphate, mmol 56.5 14.1 0.60 8.5
Zinc, µmol 382 96 0.91 87
Manganese, µmol 18.2 4.55 0.90 4.10
Copper, µmol 23.6 5.91 0.90 5.31
Chromium, µmol ND4 ND4 ND4 ND
Selenium, µmol 1.0 0.25 0.91 0.23
Iodine, µmol 0.3 0.08 0.89 0.07
Iron, mg 25.0 6.3 0.14 0.9
Cobalamin, µg 5.0 1.25 1.00 1.25
Biotin, µg 20.0 5.0 1.00 5.0
Retinol, µg 189 47 1.00 47
Ergocalciferol, µg 1.4 0.34 1.00 0.34
α-Tocopherol, mg 2.7 0.67 1.00 0.67
Phylloquinone, µg 130 32.5 1.00 32.5
Ascorbic acid, mg ND4 ND4 ND4 ND4
Thiamin, µg 380 95 1.00 95
Riboflavin, µg 1000 250 1.00 250
Pyridoxine, µg 500 125 1.00 125
Pantothenate, mg 3.0 0.75 1.00 0.75
Folate, µg 80 20 1.00 20
Niacinamide, mg 5.0 1.25 1.00 1.25
lipid      g 32 8 ND4 ND4
1. From NRC (1998) nutrients requirements for swine weighing 3 to 5 kg. 
2. Requirements above were assumed to represent a mean 4kg piglet, therefore the 
requirements were divided by 4 to estimate on a per kilogram basis. 
3. The bioavailability adjusting for incomplete intestinal absorption (Wykes et al., 1993) 
4. Not determined 
5. The calculation in this table are: Oral requirement (4 kg) /4 = Oral requirement 
(unit·kg-1·day-1); Oral requirement (unit·kg-1·day-1) X Bioavailability = Estimated 
intravenous requirement (unit·kg-1·day-1). 
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Table 3.5  Formula of the PN solution 
 
Product Nutrient concentrations in the 
product 
Volume added 
(mL·L-1) 
10% Aminosyn PF1 Amino acid 100 mg·mL-1 610
70% Dextrose2 Dextrose 700 mg·mL-1 128
23.4% Sodium Chloride3 Na 
Cl 
4.00 mmol·mL-1 
4.00 mmol·mL-1 5.4
Potassium Phosphate3 K 
PO4 
4.36 mmol·mL-1 
3.00 mmol·mL-1 5.4
Calcium Gluconate4 Ca 0.232 mmol·mL-1 75
50% Magnesium Sulfate3 Mg 
SO4 
4.15 mmol·mL-1 
4.15 mmol·mL-1 0.6
Iron Dextran Injection3 Fe 50 mg·mL-1 0.2
Vit B12 injection1 Vitamin B12  0.1 mg·mL-1 0.1
M.V.I. Pediatric3 Vitamin A 
Vitamin C 
Vitamin D 
Thiamine 
Riboflavin 
Pyridoxine 
Niacinamide 
Panthenol 
Vitamin E 
Vitamin K1 
Biotin 
Folic acid 
Vitamin B12 
460 IU·mL-1 
16 mg·mL-1 
80 IU·mL-1 
0.24 mg·mL-1 
0.28 mg·mL-1 
0.2 mg·mL-1 
3.4 mg·mL-1 
1 mg·mL-1 
1.4 IU·mL-1 
0.04 mg·mL-1 
4 μg·mL-1 
28 μg·mL-1 
0.2 μg·mL-1 
4
Micro Plus 6 Pediatric3 Zinc 
Copper 
Manganese 
Chrome 
Selenium 
Iodine 
3 mg·mL-1 
0.4 mg·mL-1 
0.1 mg·mL-1 
4 μg·mL-1 
20 μg·mL-1 
60 μg·mL-1 
8.5
Water2 H2O  163
Total    1000
1. Abbott Laboratories Canada: Montreal, Quebec, Canada. 
2. Baxter Coroperation, Mississauga, Ontario, Canada. 
3. Sabex Inc.: Boucherville, Quebec, Canada. 
4. Pharmaceutical Partners of Canada Inc., Richmond Hill, Ontario, Canada. 
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Table 3.6  Estimated requirement achieved by the PN regimen 
Nutrient 
Estimated requirement1 
(unit·kg-1·day-1) 
Concentration in the 
PN solution (unit·L-1)
Intake 
during PN2 
Requirement 
achieved by PN3
Energy 
%4 
Metabolizable energy, kcal 205 550 2145 1.04
Amino acids, g 16.3 61.0 17.1 1.05 32
Indispensable amino acids, g 6.0 30.0 8.4 1.41
Dextrose, g ND6 90.0 25.2 ND6 40
Sodium, mmol 6.14 21.46 6.01 0.98
Potassium, mmol 4.31 23.36 6.54 1.52
Calcium, mmol 7.0 17.4 4.9 0.70
Magnesium, mmol 0.59 2.21 0.62 1.06
Chloride, mmol 4.0 21.5 6.0 1.51
Phosphate, mmol 8.5 16.1 4.5 0.53
Zinc, µmol 87 393 110 1.27
Manganese, µmol 4.10 15.61 4.37 1.07
Copper, µmol 5.31 54.00 15.12 2.85
Chromium, µmol ND6 0.64 0.18 ND6
Selenium, µmol 0.23 2.18 0.61 2.64
Iodine, µmol 0.07 4.03 1.13 16.21
Iron, mg 0.9 10.71 3.00 3.33
Cobalamin, µg 1.25 11.57 3.24 2.59
Biotin, µg 5.0 17.1 4.8 0.96
Retinol, µg 47 600 168.0 3.55
Ergocalciferol, µg 0.34 8.57 2.40 7.06
α-Tocopherol, mg 0.67 6.00 1.68 2.51
Phylloquinone, µg 32.5 171.4 48.0 1.48
Ascorbic acid, mg ND 68.57 19.20 ND
Thiamin, µg 95 1029 288 3.03
Riboflavin, µg 250 1200 336 1.34
Pyridoxine, µg 125 857 240 1.92
Pantothenate, mg 0.75 4.29 1.20 1.60
Folate, µg 20 120 34 1.68
Niacinamide, mg 1.25 14.57 4.08 3.26
Lipids      g ND6 7 6.00 ND6 28
1. The estimated requirements were calculated in Table 3.6. 
2. Intake during PN for the piglets were: the PN solution 280 mL·kg-1·day-1; lipids 20 mL·kg-1·day-1. 
3. The calculation is: Concentration in the PN solution (unit·L-1) X 280 mL /1000 = Intake during PN; 
Intake during PN / Estimated intravenous requirement = Requirement achieved by PN. 
4. The calculation of energy were based on: Amino acids 4.0 kcal·g-1; Dextrose 3.4 kcal·g-1; Lipids 10.0 
kcal·g-1. 
5. The energy of intake during PN is from the PN solution and the lipids.  The calculation is :(550 kcal X 
280 mL / 1000) + (6g X 10.0 kcal·g-1) =214 kcal 
6. Not determined. 
7. The lipids were delivered separately from the PN solution. 
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3.2.3 Sample collection and analysis 
Daily weight and daily nutrients intake were recorded.  On day 0, 7, 14 and 
21, 5 mL of venous blood was taken from the vascular access catheter into a metal 
free tube. The blood was centrifuged to get the serum.  One mL serum was sent to 
the biochemistry lab in the Prairie Diagnostic Center in Western College of 
Veterinary Medicine, University of Saskatchewan, for serum alkaline phosphatase 
(ALP), gamma glutamyl transferase (GGT), and bilirubin levels.  Another 1 mL 
serum was sent to SRC for aluminum concentration.  On day 21, the animals were 
euthanized.  Urine, bile and liver samples were collected in metal free containers 
and sent to SRC for aluminum determinations.  Liver sections were also obtained 
and fixed in 10% buffered formalin.  The liver sample were processed with an 
automatic tissue processor, and stained with haematoxylin and eosin.  The liver 
slides were sent for histological evaluation to detect canalicular plugging, periportal 
inflammation and fibrosis.  The aluminum levels in the commercial products used 
for PN solutions were determined.  The aluminum concentrations in 5 random 
samples of PN solutions used for the PN group were measured. 
ALP, GGT and bilirubin were assayed on a Beckman-Coulter LX-20 by 
standard enzymatic method (Fody E.P., 2000).  PN solutions, serum, bile, urine and 
hepatic aluminum were determined at SRC by inductively coupled plasma atomic 
emission spectrometry (ICP-AES).  The pathology specimens were processed at the 
Surgical Research Laboratory, University of Saskatchewan, and evaluated by the 
veterinary pathologist at the Prairie Diagnostic Services Center, Western College of 
Veterinary Medicine, University of Saskatchewan. 
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3.2.4 Statistical methods 
Descriptive statistics was performed.  Results are expressed as mean ± 
standard deviation (SD).  One-way ANOVA and Post Hoc (Student-Newman-Keuls) 
were used to compare the variables in different groups.  Values were considered 
significant at p<0.05. 
3.2.5 Results  
The aluminum content in saline used for the Control group and for flushing 
all central venous access catheters was less than 1 μg·L-1.  The aluminum levels in 
the solutions formulated for the Low Al group (20 μg·mL-1) and the High Al group 
(1500 μg·mL-1) were confirmed by the ICP-AES testing in SRC.  The aluminum 
content of all the solutions used in the PN group was measured (Table 3.7).  Based 
on the formulation of PN solution, the aluminum content of PN solution for the 
piglet was calculated at 350.1 μg·L-1.  The mean aluminum content of 5 random PN 
solutions was 332.4±7.7 μg·L-1 (322 to 342 μg·L-1).  Based on the amount of the 
fluids delivered by PN in the piglets, the mean aluminum intake for PN group was 
estimated at 37.8±14.3 μg·kg-1·day-1 (Table 3.8). 
There was no significant difference in growth patterns among the control 
group, the Low Al group and the High Al group (Table 3.9).  At day 14 and day 21, 
the bodyweights of the PN group was significantly lower than other three groups 
(Figure.3.7).  Serum ALP and GGT levels was shown in Table 3.10.  Serum ALP 
was significantly elevated in the Low Al and High Al group at day 7.  There was no 
significant difference among four groups in mean serum ALP at day 0, day 14, and  
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Table 3.7  Aluminum content in PN solutions 
 
Product1 
Aluminum 
(μg·L-1) 
PN solution 
(mL·L-1) 
Aluminum4 
(μg) 
10% aminosyn PF <502 610 15.3 
70% Dextrose <502 128 3.2 
23.4% Sodium Chloride <1002 5.4 0.3 
Potassium Phosphate  6300 5.4 34.0 
Calcium Gluconate  3900 75 292.5 
50% Magnesium Sulfate  <3002 0.6 0.1 
Iron Dextran  3200 0.2 0.6 
Micro Plus 6 Pediatric 290 8.5 2.5 
M.V.I. Pediatric 375 4 1.5 
VitB12  <502 0.1 0.0 
water  0.7 163 0.1 
30% Intralipid3 60  
Total  1000 350.1 
1. The nutrient contents and manufactures of the products were listed in Table 3.3. 
2. When the aluminum levels under the detection limits, half of the value was used 
in the calculation. 
3. One mL contains 30 mg lipids.  Fresenius Kabi AB, Uppsala, Sweden. 
4. The calculation of aluminum is: Aluminum (μg·L-1) X PN solution (mL·L-1) / 
1000 = Aluminum (μg) 
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Table 3.8  An example of the calculation of aluminum intake from PN therapy 
in the PN group piglets1 
 
 Aluminum 
content  
(μg·L-1)  
Intake from PN 
therapy 
(mL·kg-1·day-1) 
Aluminum intake6 
(μg·kg-1·day-1) 
PN solutions2 332.43 121 40.2
30% intralipids4 605 14 0.8
Total  41.0
1. The intake from PN therapy is from the piglet (subject 31) in the PN group at the 
day 5 of the experiment.   
2. The formula of PN solutions for the piglets was listed in Table 3.7. 
3. The aluminum amount in the solution was the mean of 5 random samples 
determined at Saskatchewan Research Council (SRC), Saskatoon. 
4. One mL contains 30 mg lipids.  Fresenius Kabi AB, Uppsala, Sweden. 
5. The amount of aluminum was determined at Saskatchewan Research Council 
(SRC), Saskatoon. 
6. The calculation of aluminum intake is: Aluminum content (μg·L-1) X Intake from 
PN therapy (mL·kg-1·day-1) / 1000 = Aluminum intake (μg·kg-1·day-1) 
  77
Table. 3.9  The mean body weight of piglets on Day 0, 7, 14 and 21. 
Weight (g) Group 
Day 0 Day 7 Day 14 Day 21
Control 
(n=5) 
2220±259 4040±476 5960±442a 8300±774a 
Low Al 
(n=7) 
1857±544 3836±1098 5843±1300a 7585±1570a 
High Al 
(n=6) 
2275±555 4058±498 5975±1145a 8542±1700a 
PN  
(n=6) 
2383±634 3417±694 4625±539b 5463±5621,b 
Data was expressed as mean±SD.  One-way ANOVA and Post Hoc test 
(Student-Newman-Keuls) was used to compare means.  Means with different 
superscripts were significantly different (p<0.05).  
1. n=4 at day 21 in PN group. 
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 7 14 21
days
bo
dy
w
ei
gh
t (
g)
c o n t r o l  g r o u p ( n = 5 )
L o w  A l  g r o u p ( n = 7 )
H i g h  A l  g r o u p ( n = 6 )
P N  g r o u p ( n = 6 )
 
Figure 3.7  The pattern of growth in all piglets 
 
The symbols (■, ♦,▲, and * ) represent means.  n=4 at day 21 in PN group.  The mean body weights in PN group piglets at 
day 14 and day 21 were significant lower than other three groups. 
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Table 3.10  The mean serum ALP, GGT and total bilirubin of the piglets during the experimental period  
 
ALP (U·L-1) GGT (U·L-1) Total bilirubin (μmol·L-1) Group 
Day 0 Day 7 Day 14 Day 21 Day 0 Day 7 Day 14 Day 21 Day 0 Day 7 Day 14 Day 21 
Control 
(n=5) 
1282±349 1138±564a 749±266 529±87 47±10 60±21 55±20a 60±28a 1.0±0.7 1.8±1.1a 2.2±1.3a 1.6±0.9a 
Low Al 
(n=7) 
1654±525 2406±778b 901±410 403±200 38±12 42±14 31±6a 29±10a 1.7±0.9 3.1±1.7a 2.7±1.5a 3.0±1.4a 
High Al 
(n=6) 
1682±726 2257±421b 1458±572 799±389 48±21 58±23 58±35a 47±33a 1.3±0.8 5.7±1.4b 6.8±1.3b 7.2±1.6b 
PN (n=6) 3222±2782 1239±753a 989±522 802±2991 37±13 43±18 147±124b 130±891,b 2.0±0.6 13.5±17.4c 62.8±38.9c 109.5±57.31,c 
Data was expressed as mean±SD.  One-way ANOVA and Post Hoc test (Student-Newman-Keuls) was used to compare means.  
Means with different superscripts (a, b, c) were significantly different (p<0.05) when compare to each other.  The normal value for 
serum ALP is 110-340 U·L-1, for serum GGT is 0-25 U·L-1, for serum total bilirubin is 0-4 μmol·L-1. 
1. PN group only had 4 piglets at day21. 
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day 21.  A significant elevation in mean serum GGT showed in the PN group at day 
14 and day 21 (Table 3.10).  
The mean serum total bilirubin was significantly increased in the High Al and 
PN group at day 7, 14, and 21 (Table 3.10).  Note that 2 of 7 (28.6%) piglets in the 
Low Al group had serum bilirubin over 4 μmol·L-1 (normal value).  The mean 
serum aluminum concentration was significantly increased in the High Al group at 
day 7, 14 and 21 (Table 3.11).  For other three groups, there were no significant 
differences for mean serum aluminum concentration during the experimental period.   
Mean liver aluminum concentrations at the end of the study were significantly 
elevated in all three experimental groups when compared to the Control group and 
they were dose dependant (Table 3.11).  Mean urine aluminum concentrations at the 
completion of the experiment were significantly increased in the PN group and the 
High Al group, but not in the Low Al group.  Mean bile Al concentrations were 
elevated only in the Low Al group at the end of the study.  However, it should be 
noted that for 3 of 6 piglets in the PN group and 1 of 6 piglets in the High Al group, 
there was no bile can be obtained at the end of study.  
Histological evidence of mild to moderate cholestasis was observed in 1 
control subject, 2 Low Al subjects, 1 High Al subject and all 6 subjects in the PN 
group (Table 3.12). 
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Table 3.11  Serum, liver, urine and bile aluminum concentrations in the piglets  
 
 
Data was expressed as mean±SD.  When the concentration was under the detected limitation, half of the value was used in the 
calculation. One-way ANOVA and Post Hoc test (Student-Newman-Keuls) was used to compare means.  Means with different 
superscripts (a, b, c) were significantly different (p<0.05) when compared to each other.  
1. n=4, PN group only had 4 piglets at day21. 
2. n=5, for one piglet in High Al group there was no bile could be obtained at the end of the study. 
3. n=3, for three piglets in PN group there were no bile could be obtained at the end of the study. 
Serum aluminum (μg·L-1) Group 
Day 0 Day 7 Day 14 Day 21 
Liver aluminum 
(μg·g-1) 
Urine aluminum 
(μg·L-1) 
Bile aluminum 
(μg·L-1) 
Control 
(n=5) 
46±32 20±11a 33±37a 38±32a 0.05±0.06a 19±7a 16±2
Low Al 
(n=7) 
53±50 239±324a 126±97a 79±74a 0.87±0.60b 84±93a 64±46
High Al 
(n=6) 
27±16 1187±473b 1036±753b 880±807b 71.33±7.78c 1521±1937c 289±3852 
PN  
(n=6) 
14±4 45±34a 45±16a 37±221,a 0.90±0.37b 259±198b 17±103 
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 Table 3.12  The histological changes in the piglets 
Subject 
number 
Normal liver Mild 
hepatitis 
Minimal 
hepatic 
fibrosis 
Mild 
extramedullary 
haematopiesis 
Mild to 
moderate 
cholestasis 
Control      
11   X   
14  X    
16     X 
21  X    
25 X     
Subtotal 
(n=5) 
n=1 n=2 n=1 n=0 n=1 
Low Al      
7  X    
8  X    
9  X  X  
10    X  
20  X   X 
24 X     
26  X   X 
Subtotal 
(n=7) 
n=1 n=5 n=0 n=2 n=2 
High Al      
18  X    
19 X     
27  X  X  
28  X X   
29    X  
30  X  X X 
Subtotal 
(n=6) 
n=1 n=4 n=1 n=3 n=1 
PN      
31     X 
32     X 
33     X 
34     X 
35    X X 
36    X X 
Subtotal 
(n=6) 
n=0 n=0 n=0 n=2 n=6 
Total (n=24) n=3 n=11 n=2 n=7 n=10 
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3.2.6 Discussion 
A neonatal piglet model was developed to investigate aluminum in PNAC.  
The growth pattern was an important consideration in model development.  Despite 
the different doses of intravenous aluminum, the piglets in the control, Low Al and 
High Al group had a similar growth pattern.  The body weight of piglets in the PN 
group was significant lower than the other three groups after day 7.  It is also 
significant that all groups other than the PN group had free access to food.  A slow 
growth pattern was also seen in the infants who were on PN therapy, especially for a 
long term (Putet, 1993).   
Intravenous aluminum used in the Low Al group represents the current 
aluminum contaminant level of PN solutions in the hospitals.  The high dose used 
in the High Al group was 1500 μg·kg-1·day-1, which was the dose used in Klein’s 
study (Klein, et al., 1987).  The differences were that the animals in Klein’s study 
were 6-week old piglets and the experimental time was 50 days (Klein et al., 1987).  
This High Al group was an external control in the study.  The significant elevated 
serum aluminum levels and elevated total bilirubin levels in this group verified 
Klein’s work and demonstrated that the piglet model was effective to study the role 
of aluminum in cholestasis. 
A significant elevation in serum total bilirubin indicating the development of 
cholestasis was found in the High Al group and the PN group, but not in the Low Al 
group.  This suggested that high dose parenteral aluminum might play a role in the 
development of cholestasis.  The data confirmed previous animal studies that 
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aluminum could cause hepatic dysfunction.  PNAC was developed in the PN group.  
However, the failure to demonstrate this change in the Low Al group would make 
caution in extrapolating the role of aluminum in the development of PNAC into 
clinical situations.  The elevated serum bilirubin in the PN group agreed that other 
factors such as PN therapy or lack of enteral feeding might interplay with parenteral 
aluminum in the development of cholestasis.  Serum total bilirubin kept climbing 
during the experiment in the PN group.  Thus, a relationship between the time on 
PN and the degree of cholestasis was implied in the PN group.  Although there was 
no significant difference in serum total bilirubin found in the Low Al group, two of 
seven piglets (piglet 7 and piglet 8) had an abnormal value (see Table 6.3 in 
Appendix D).  This indicated that the hepatic dysfunction might be present in these 
two piglets. 
Serum ALP showed a mixed result in the piglets.  Serum GGT only 
significantly elevated on day 14 and day 21 in the PN group.  The data from both 
piglets and infants suggested that serum ALP and serum GGT were not good 
markers of cholestasis.  There are other liver enzymes such as serum alanine 
aminotransaminase (ALT, or SGPT) and aspartate aminotransaminase (AST, or 
SGOT), which could be used as the markers of liver cell injury.  However, the 
common causes of the elevations in ALT and AST are fatty liver diseases seen most 
often in those with obestity, diabetes or elevated blood lipids, but not in cholestasis 
(Fody, 2000). 
Serum aluminum level was significantly elevated only in the High Al group.  
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Note that high standard deviation was found in serum aluminum concentration both 
in the piglets and the infants.  Different abilities to excrete the aluminum into urine 
or bile may affect the serum aluminum levels.  Moreover, the rate of aluminum 
deposition in the organs may differ among the individual subjects.  Therefore, even 
under the same contaminated aluminum level, serum aluminum may not reflect the 
parenteral aluminum intake.  High variable bile and urine aluminum concentrations 
in the piglets may reflect differing excretion capabilities.  And without the 
correlation with serum total bilirubin in piglets, serum aluminum was not a good 
indicator of cholestasis.  Similar result was shown in our infant study.  Previous 
human studies of infants on long term PN therapy suggested an elevated serum 
aluminum concentration (Moreno et al., 1994; Koo et al., 1986).  Thus, further 
research is required to demonstrate if the trend of serum aluminum would go up 
again with the continuing unsafe aluminum loading.   
Liver aluminum concentration was significantly (p<0.05) elevated in all the 
groups compared to the control group and the relationship was dose dependant.  
Hepatic aluminum accumulation may in some way cause injury of the liver.  A 
recent study has shown a chronic aluminum exposure impaired the biliary secretory 
function and caused cholestasis in rats (Gonzalez et al., 2004).  The concentrations 
of aluminum deposited in the liver of the experimental group of piglets, especially 
the Low Al group and the PN group were lower than those found in chronically 
loaded infants receiving aluminum contaminated PN solutions (Klein et al., 1984).  
The explanation could be: 1. The excretion of aluminum in these piglets was higher 
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than the chronically loaded infants; 2. The rate of aluminum hepatic deposition was 
different between these piglets and the infants; 3. The experimental time was shorter 
than the duration of PN therapy in the infants.  Therefore, extending the experiment 
time may increase the accumulation of aluminum in the liver, and further liver 
damage may show in the Low Al group piglets.  More information about the 
aluminum excretion ability and hepatic deposition in both piglets and infants would 
be helpful. 
The failure to detect consistent histological signs of cholestasis in the High 
Al group suggested that the elevation of serum total bilirubin may precede or be 
independent of the appearance of other hepatic pathology as has been suggested to 
occur in cholestasis.  No positive hepatic histology findings have also been shown 
in previous animal models (Klein et al., 1987; Klein et al., 1988).  The histological 
findings of cholestasis in the PN group confirmed that more severe cholestasis 
developed in these piglets. 
Although we had the aluminum content of urine and bile evaluated at the end 
of the study, more information was required to determine the excretion ability of the 
piglets.  Small sample size was another limitation of the study.  A longer 
experiment time may help to see more significant results, especially in the Low Al 
group. 
3.2.7 Conclusion 
A neonatal piglet model was successfully developed to investigate the role of 
aluminum in PNAC.  Hepatic aluminum accumulation was found and it was dose 
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dependent.  High dose of intravenous aluminum or PN therapy with contaminated 
aluminum can cause cholestasis in the piglets.  However parenteral aluminum alone, 
at doses comparable to contamination level of PN therapy in the infants did not.  
Serum aluminum levels did not directly correlate with the development of 
cholestasis.  This may due to the differing excretion capabilities of the piglets.  
The current aluminum contaminated level in PN solutions may interact with other 
potential factors such as PN therapy or lack of enteral feeding and play a role in 
PNAC.
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4. SUMMARY AND FUTURE DIRECTIONS 
PNAC is a common complication of PN therapy in infants.  The etiology of 
PNAC is still unclear and is likely to be multifactorial.  The potential factors which 
have been previously implicated include prematurity, low birth weight, lack of 
enteral feeding, duration of PN and sepsis.  Also, the components of PN solution 
including the nutrients and the contaminants, such as aluminum, have been 
considered as potentially causative factors.  Aluminum contaminated in PN 
solutions bypasses the gastrointestinal barrier and directly enters the circulation, 
leading to accumulation in the liver.  However, the exact role of aluminum in PNAC 
required further research. 
We investigated the role of aluminum in human infants with gastrointestinal 
failure who required PN by monitoring the relationship between serum aluminum 
concentration and serum direct bilirubin concentration.  Demographical information 
was collected including: birth weight, gestation age, and diagnosis.  Serum 
aluminum and bilirubin (direct and indirect) concentrations were determined on days 
0, 7, 14, and 21.  PNAC was diagnosed in infants with a serum direct bilirubin ≥34 
μmol·L-1.  Aluminum concentrations were also measured in representative samples 
of PN solutions.  This was used to estimate the daily intake of aluminum per 
kilogram of body weight from PN.  By the end of the study (21 days), 5 of 16 
(31.3%) infants developed PNAC.  We found that serum aluminum concentrations 
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peaked at day 7 of PN therapy and declined thereafter.  There was no significant 
difference in serum aluminum concentrations between PNAC and non-PNAC infants.  
Furthermore, a significant correlation between the serum direct bilirubin and serum 
aluminum concentrations was not observed.  There were no significant differences 
between the PNAC and non-PNAC group in birth weight, gestation age and duration 
of PN therapy. 
Without the significant findings between serum aluminum and the 
development of PNAC in infants, the role of aluminum in PNAC is blurred.  The 
comparison of different doses of parenteral intake of aluminum will give more 
details of the role of aluminum in this disease.  The evaluation of not only serum 
aluminum concentration, but also the aluminum levels in liver, urine and bile will 
help to understand the whole picture of aluminum in this disease.  For practical and 
ethical reasons, this type of study would be best conducted in an animal model.  We 
developed a piglet model to further study the relationship between different doses of 
intravenous aluminum or PN therapy and the development of cholestasis.  
Twenty-four piglets, 2 to 4 days old, underwent insertion of a silastic central venous 
access catheter and received either daily intravenous (i.v.) aluminum injections or 
PN solutions for 3 weeks.  The groups were: 1. Control group (n=5); 2. Low Al 
(aluminum) group (n=7), intravenous (iv) injection with aluminum dose at 20 
μg·kg-1·day-1 (the approximate aluminum level in PN solutions for the infants); 3. 
High Al (aluminum) group (n=6), iv with aluminum dose at 1500 μg·kg-1·day-1 (the 
level caused cholestasis in pigs by a previous investigator); 4. PN (parenteral 
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nutrition) group (n=6), PN solutions with a mean aluminum dose at 37.8±14.3 
μg·kg-1·day-1.  Serum bilirubin and aluminum was measured on day 0, 7, 14, 21.  
At the completion of the study, urine, bile, and liver aluminum concentration were 
measured.  The piglet study demonstrated that aluminum concentrations 
comparable to contamination levels in current PN solutions (20 µg·kg-1·day-1) were 
unable to produce cholestasis in piglets by 21 days.  However, cholestasis did 
develop in the piglets with the high dose aluminum (1500 µg·kg-1·day-1) treatment 
and in the piglets with PN therapy (the aluminum dose was 37.8±14.3 µg·kg-1·day-1).  
Hepatic aluminum accumulation was found in all experimental piglets and it was 
dose dependent.  The result of this study showed that the hepatic accumulation of 
aluminum occured even in the low level of parenteral intake of aluminum (20 
µg·kg-1·day-1) by 21 days. 
The components of PN solutions in both infant and piglet study were the 
same as the components used in the local hospital.  The mean aluminum parenteral 
intake in the infant study was 21.6 µg·kg-1·day-1.  Five of sixteen (31.3%) infants 
developed cholestasis by 21 days.  In the piglet study, the low aluminum group with 
the similar aluminum intake (20 µg·kg-1·day-1) did not develop cholestasis.  
However, cholestasis developed in the high aluminum group (1500 µg·kg-1·day-1) 
and PN group (aluminum intake was 37.8±14.3 µg·kg-1·day-1) by 21 days.  The 
difference of aluminum intake between the infants and the PN group piglets was due 
to the different requirements of infants and piglets.  The nutrients requirements of 
piglets are much higher than the infants.  It would be interesting to see: 1. If we 
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extend the experimental time, would the piglets in the low aluminum group develop 
cholestasis? 2. If the 37.8 µg·kg-1·day-1 aluminum level was used in the piglets, 
would that result in cholestasis?  The aluminum concentration in PN solutions may 
vary based on the different products and manufactures.  In the United States, the 
legislation was made to limit the amount of aluminum in the PN solutions.  The 
aluminum levels in the large volume solutions such as amino acids, dextrose, and 
lipids must less than 25 µg·L-1.  However, there was no limitation for the small 
volume solutions such as calcium gluconate, which was the major contributor of 
aluminum contamination.  The aluminum in the component of calcium gluconate 
accounted for more than 80% of total aluminum in both infant and piglet PN 
solutions (83% in the piglet PN solution and 85% in the infant PN solution, see 
Table 3.2 and Table 3.7).  Since aluminum is hard to remove by the manufactures, 
minimizing the amount of calcium gluconate in the PN solution would significantly 
reduce the aluminum contaminate level.  There is still not enough data in infants to 
define a safe level.  Additional human studies need to be conducted to more fully 
explore this issue. 
The wide variation of serum aluminum levels was found in both infant and 
piglet studies.  Since there was similar parenteral intake of aluminum in both 
studies, the variation in serum aluminum levels may be due to different abilities to 
excrete aluminum.  Moreover, the rate of aluminum deposition in the organs may 
differ among the individual subjects.  The high variable bile and urine aluminum 
concentrations in the piglets reflected the differing excretion capabilities.  However, 
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the data on the individual physiology in the handling and excretion of aluminum was 
not completed.  The total amount of aluminum excreted in urine or in bile was not 
assessed.  The limited data from previous studies on this issue requires further 
studies. 
The diagnosis of cholestasis is made on the basis of the elevated serum direct 
bilirubin.  In the infant study, PNAC was diagnosed when the serum direct bilirubin 
was greater than 34 µmol·L-1.  The diagnosis standard was adapted from the 
previous infant studies.  The normal value of serum direct bilirubin in infants is 0 to 
5 µmol·L-1.  We found that 13 of 16 infants had a direct hyperbilirubinemia (serum 
direct bilirubin greater than 5 µmol·L-1).  Only 5 infants reached the diagnostic cut 
line (serum direct bilirubin greater than 34 µmol·L-1) by the end of the study.  
Direct hyperbilirubinemia is abnormal and is seen in association with PN therapy.  
Setting the level of 34 µmol·L-1 as the diagnosis of PNAC is arbitrary.  Selecting a 
lower value increases the incidence but also increases the risk of false PNAC.  
However, the current level is much higher than the normal level.  Further more, the 
evidence to support the current diagnostic standard which has been used by most of 
the investigators can hardly be found. 
The aim of the animal model is to provide a comprehensive and in-depth 
picture of the role of aluminum in PNAC.  Piglets were selected because of the 
similarity of liver function and bile secretion between human infants and neonatal 
piglets.  The piglets enrolled in our study were healthy and the infants were sick.  
The mean weight gained in the piglets by 21 days was 252±31 g·day-1, which was 
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much higher than the mean weight gained in the infants (16±22 g·day-1) during the 
study.  The different grow rate may affect the rate of maturity of liver and kidney in 
these subjects.  Limited data can be found comparing liver and kidney functions 
between infants and piglets in the first 3 weeks of life.  The neonatal piglet model 
also does not represent premature human infants in physiology.  Development of a 
preterm piglet model may help to better understand PNAC in premature infants. 
PNAC developed within 21 days in 5 infants.  In the piglet study, two group 
piglets (High aluminum and PN group) developed cholestasis, but not in the piglets 
in the Low aluminum group.  A statistically significant correlation between serum 
aluminum concentration and serum bilirubin was not observed in both infant and 
piglet studies.  The impact of aluminum in cholestasis may depend on the amount 
of parenteral intake of aluminum and the presence of other potential factors.  The 
interaction between aluminum and other potential factors requires further research, 
especially at the low aluminum level. 
Since the accumulation of aluminum in the liver was shown in the piglet 
study and it was dose dependent, the relationship between hepatic aluminum deposit 
and the transport system of hepatocyte would further clarify the mechanism of 
aluminum in PNAC.  A recent study showed that chronic exposure to aluminum 
impaired the hepatic handling of organic anions by decreasing both sinusoidal uptake 
and canalicular excretion in rats (Zambrano et al., 2004).  Additional studies are 
needed to confirm and clarify the exact mechanism through which aluminum wields 
these harmful effects.  The recent opening of the Canadian Light Source on the 
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University of Saskatchewan campus may help us to know more details about the 
microstructures of hepatic tissues of our animal model.  This kind of microscopic 
evaluation has not been reported. 
In conclusion, our results showed that the role of aluminum in cholestasis 
may depend on the amount of parenteral intake of aluminum.  Other factors such as 
the individual ability to excrete aluminum, and the lack of enteral nutrition, may play 
complimentary roles.  The result of infant study has significantly contributed to the 
previously limited data of aluminum in infants with PNAC.  One of the limitations 
of the infant study is the sample size.  Expanding the sample size and extending the 
experimental time may show some statistical significance.  The individual ability to 
excrete aluminum will be assessed in both infant and piglet study in the future.  
Different doses of aluminum other than 20 µg·kg-1·day-1, such as 40 µg·kg-1·day-1, 
will be used in the developed piglet model to further study the role of aluminum in 
PNAC.  Other types of piglet model such as a preterm neonatal piglet model will be 
developed based on the experiences of this model.  The better understanding of the 
process involved in the development of PNAC would significantly contribute to the 
interventions for reducing the incidence and the severity of this disease in infants.
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PROTOCOL 
THE ROLE OF ALUMINUM IN THE PARENTERAL NUTRITION 
ASSOCIATED CHOLESTASIS IN INFANTS 
 
Investigators: Dr. G. Miller, Dr. G. Zello 
Graduate Student: Mei Li 
Contact: Mei Li at 9665831 
 
Parenteral nutrition associated cholestasis (PNAC) is a common complication of  
parenteral nutrition (PN) in infants.  It has been demonstrated in experimental 
models and early human studies that the contaminant aluminum in the PN solutions 
is related to the development of cholestasis.  Our objective is to measure the 
relationship between the development of cholestasis in infants receiving PN and the 
concentration of aluminum in these infants blood. 
 
Inclusion criteria:  Infant, age <365 days 
               Gastrointestinal failure: gastroschesis, intestinal atresia, 
omphalocele, necrotizing eterocolitis, intestinal aganglionosis 
 
Exclusion criteria: 1. Congential  hepatic or biliary disorder such as: extrinsic 
obstruction of the biliary system, hepatic neoplasm, 
inspissated bile syndrome, spontaneous perforation of the 
common bile duct, infantile obstructive cholangiopathy 
(neonatal hepatitis, biliary atresia, biliary hypoplasia, 
choledochal cyst, Alagille’s syndrome) 
2. Major cardiac anomaly 
3. Other congenital or acquired disorders which may cause 
hepatic disease such as: hepatitis, syphilis, rubella, 
toxoplasmosis, metabolic disorders (i.e., galactosaemia, 
fructosaemia, alpha-1-antitrypsin deficiency, cystic fibrosis) 
and endocrine disorders (i.e., hypothyroidism, hypopituitarism, 
hypoadrenalism) 
 
Methods: 
1. Identify potential subjects 
2. Contact Mei Li at 9665831, College of Pharmacy and Nutrition, U of S 
3. Obtain informed consent 
4. Draw baseline bloodwork: 2mL blood in the metal free tube (blue cap, 
supplied by Mei Li in the research binder on the shelf in NICU). 
5. Obtain weekly bloodwork for 3 weeks: same as baseline 
6. Fill the reminder form of bloodwork. 
 
  116 
 
 
BLOOD WORK REMINDER FORM 
The Role of Aluminum in Parenteral Nutrition Associated Cholestasis in Infants 
 
 
Investigators: Dr. G. Miller, Dr. G. Zello 
Graduate Student and Contact Person: Mei Li (966 5831) 
 
 
Patient’s name: 
PIN: 
 
Bloodwork: Please check off when blood work is done. 
 
 Day 0 Day 7 Day 14 Day 21 
Total bilirubin     
Direct / indirect     
Alkaline Phosphatase (ALP)     
Gamma glutamyl transferase (GGT)     
Aluminum     
? Use the Navy tube supplied by the investigators. 
? Label “Aluminum blood work” with EC# 2000-96. 
? Send all the blood to the lab in RUH. 
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PROTOCOL 
THE ROLE OF ALUMINUM IN THE PARENTERAL NUTRITION 
ASSOCIATED CHOLESTASIS IN PIGLETS 
 
Investigators: Dr. G. Miller, Dr. G. Zello 
Graduate Student: Mei Li 
Contact: Mei Li at 9665831 
 
A week before 
• Set up the starting date, check the availabilities of the labs needed in the 
study and inform all the staffs involed 
Dr. G. Miller, Michele, Dawna 
Prairie Swine Center, surgery lab, animal housing, sterile lab 
 
Day 0 (Monday) 
• (8:00-9:00) Piglets (2-3 days old) are usually arrive on Monday morning and 
reception weights are obtained (Health science building). 
• (9:00-12:00) PN solutions and injectable aluminum solution preparation 
(sterile lab). 
• (13:00) Surgery, catheter is placed and baseline blood work is drawn.  
• (20:00) Check the piglets to see if it is awake after the surgery. 
 
Day 1 (Tuesday) to Day 21 (Monday) 
• (8:00-10:00) Weight the piglets, record intake, clean up the cage and floor, 
give daily aluminum injection. Draw blood every Monday (on day 7,14, and 
21). 
• (10:00-12:00) PN solutions preparation 
• (12:00) Change the PN bags, adjust the pump rates to achieved the 
requirement 
• Day 21, animals are euthanized, urine, bile, liver and kidney are obtained. 
Liver is harvested, weighted, section taken for staining, another section 
frozen for aluminum determination, the left section is frozen for storage. 
• Send serum sample to the Western College of Veterinary Medicine for liver 
function tests 
• Send serum, urine, bile, liver, PN solutions, injectable aluminum solutions 
for aluminum determination at SRC. (Call Brenda in advance) 
• Once the slides of the liver are prepared, take them to Prairie Diagnostics 
Center for pathology reading in the Western College of Veterinary Medicine. 
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PROTOCOL FOR PN SOLUTIONS PREPARATION 
 
1. Laminar airflow hood (LAH) should be started and run for 30 minutes prior to 
cleaning and compounding in the hood. 
2. Clean LAH first with the germicide cleaning solution 
3. Clean LAH with 70% alcohol solution. 
4. All products introduced into the LAH if not removed from an over-wrap should 
be sprayed with 70% alcohol prior to placing in the LAH. 
5. Over-wrap should be opened at the edge of the LAH to minimized particulate 
matter in the critical workspace area. 
6. Clamp all tube feeds into the PN bag. 
7. Spike 1 vented lead into the glass amino acid bottle. 
8. Spike 1 vented lead into the dextrose bag. 
9. Hang the bottle and the dextrose bag on the IV bar in the LAH and tare the PN 
bag on the scale. 
10. Release clamp on the dextrose lead and by gravity drain into the PN bag to the 
desired weight. Re-clamp lead. 
11. Tare scale. Release clamp on the amino acid lead and by gravity drain into the 
PN bag to the desired weight. Re-clamp lead. 
12. Remove transfer spike from dextrose bag and discard and aseptically spike the 
sterile water bag. Tare the scale. Release clamp on the sterile water lead and by 
gravity drain into the PN bag to the desired weight. Re-clamp lead. 
13. Disconnect lead set and seal PN bag. 
14. Mix the solution thoroughly until no dextrose strands can be seen in the 
solution. 
15. Draw up additives by syringe and add in the following order ensuring a 
thorough mixing after each additive is added to the solution. 
A. Calcium gluconate 
B. Sodium chloride 
C. Magnesium sulphate 
D. Iron 
E. Micro plus 6 pediatric 
F. Potassium phosphate 
16. vitamin B12 and MVI pediatric should be added to the solution just prior to 
administration. 
 
 
  119 
 
 
ALUMINUM INJECTION PREPARATION 
 
The aluminum injections for the Low and High aluminum (Al) piglets were 
in the form of aluminum chloride hexahydrate (AlCl3.6H2O) (Fisher Scientific, 
Mississauga, Ontario, Canada).  The aluminum was mixed in 250 mL bags (Abbott 
Laboratories, Montreal, Quebec, Canada) of normal saline (Abbott Laboratories, 
Montreal, Quebec, Canada).  The final concentrations of the solution were 20 
μg·mL-1 for the Low Al group and 1500 μg·mL-1 for the High Al group. 
  
The procedure: 
1. Using aseptic techniques, dissolve 0.0447 g (for 20 μg·mL-1) or 3.3542 g (for 
1500 μg·mL-1) AlCl3.6H2O in approximately 10 mL of sterile water (Baxter 
Coroperation, Mississauga, Ontario, Canada).  
2. Transfer and filter the solution into an empty intravenous (iv.) bag (Abbott 
Laboratories, Montreal, Quebec, Canada) and then mix with normal saline 
(Abbott Laboratories, Montreal, Quebec, Canada) to 250 mL. 
3. Label the bag and store in the fridge. 
Note: The same lot numbers of aluminum chloride hexahydrate, saline, and sterile 
water were used for each bag prepared. 
 
The calculation notes: 
1. To manufacture a concentration of 20 μg·mL-1 (or 1500 μg·mL-1) of Al3+ using 
AlCl3.6H2O 
2. AlCl3.6H2O has a molecular weight of 241.5. 
3. Every 241.5 μg of AlCl3.6H2O contains 27 μg Al3+. 
4. X μg AlCl3.6H2O must be added to each mL to form 20 μg·mL-1 (or 1500 
μg·mL-1) Al3+ solution. 
20 μg·mL-1 (or 1500 μg·mL-1) / X μg·mL-1 = 27 μg / 241.5 μg 
X = 178.9μg·mL-1 (for 20 μg·mL-1) or X = 13416.7 μg·mL-1 (for 1500 μg·mL-1) 
5. For a 250 mL bag 
20 μg·mL-1: 178.9 μg·mL-1 x 250 mL = 44725 μg = 0.0447 g 
1500 μg·mL-1: 13416.7 μg·mL-1 x 250 mL = 3354175 μg = 3.3542 g 
6. 0.0447 g AlCl3.6H2O was transferred into a 250 mL bag to result in a 
concentration of 20 μg·mL-1 Al3+ solution. 
3542 g AlCl3.6H2O was transferred into a 250 mL bag to result in a 
concentration of 1500 μg·mL-1 Al3+ solution. 
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Appendix C 
 
Results from the individual infants 
 
This appendix lists the results of all 16 infants in the prospective study.   
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Table 6.1  Results from the individual patients in the PNAC group in the infant prospective study 
 
Direct bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Patient Gender Birth 
weight 
(g) 
Gestation 
age 
(weeks) 
Duration 
of PN 
(days) 
Diagnosis 
Day0 Day7 Day14 Day 21 Day0 Day7 Day 14 Day 21 
1 male 1510 31 19 Intestinal atresia 14 54 100 68  530 410 290 
3 male 1670 32 12 Intestinal atresia 5 7 49  40 370 15 15 
4 male 2380 35 12 Gastroschisis 0 15 27 46 15 20 15 15 
11 male 2290 36 21 Intestinal atresia 6 18 32 42 40 1050 40 40 
15 male 3120 38 16 Meconium peritonitis 16 26 36  75 710 150  
The empty spaces in the table indicated that the infant was discontinued the PN therapy. 
 
  122 
 
 
 
 
Table 6.2  Results from the individual patients in the non-PNAC group in the infant prospective study 
 
Direct bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Patient Gender Birth 
weight 
(g) 
Gestation 
age 
(weeks) 
Duration 
of PN 
(days) 
Diagnosis 
Day0 Day7 Day14 Day 21 Day0 Day7 Day 14 Day 21 
2 male 3627 40 7 Intestinal atresia 11 0   15 260   
5 female 3050 36 10 Gastroschisis 5 14 13 21 450 40 150 15 
6 female 3030 38 15 Gastroschisis 0 10 7 7 110 640 240 52 
7 female 2720 37 14 Gastroschisis 0 0 0  40 970 91  
8 female 2540 38 9 Intestinal atresia 5 7   260 15   
9 female 1700 33 10 Intestinal atresia 5 9 18 13 440 1420 460 15 
10 female 2470 35 25 Gastroschisis 5 6 0 11 20 200 99 15 
12 male 900 26 35 Intestinal atresia 10 8 10 12 40 1050 40 40 
13 male 3300 42 13 Intestinal atresia 7 0 0  40 90 15  
14 male 3150 39 11 Gastroschisis 6 11   40 520   
16 male 1360 31 30 Gastroschisis 5 7 28 27 15 40 80 80 
The empty spaces in the table indicated that the infant was discontinued the PN therapy. 
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Appendix D 
Quality control of aluminum analysis 
The concentration of aluminum was determined at Saskatchewan Research 
Council (SRC), Saskatoon by Inductively Coupled Plasma Atomic Emission 
Spectroscopy (ICP-AES).  The ICP-AES contains a plasma, a spectrometer and a 
detector.  The plasma is a stream of Argon gas that is ionized by an applied radio 
frequency field and where the specific elements emit light.  The spectrometer can 
separate the characteristic wavelengths, and the detector can measure the emission 
spectra.  The detectable limit is 30 µg·L-1.  A variety of quality control techniques 
are used to ensure the validity of routine analytical results.  With each technique, 
results must be within specified limits or corrective action is taken.  Quality control 
was performed on: 
1. Control standards of aluminum (prepared by SRC) and standard reference of 
aluminum (prepared by the author) are analyzed with each batch of samples. 
2. One of every ten samples, which was analyzed in duplicate.  The limit of 
quantification is within 10%. 
3. Control standards of aluminum (prepared by SRC) were analyzed after every five 
samples to check the calibration. 
4. In each batch of samples, sample matrix effects are checked by spiking one 
sample with a known amount of aluminum standard (prepared by SRC) and 
measuring the recovery of the aluminum in the sample.  The rate of recovery is 
within the range from 95% to 105%. 
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Appendix E 
Techniques in the piglet model development 
This appendix describes some techniques used to resolve the problems we 
encounter in the piglet model.  A total of 36 piglets were studied, including the pilot 
study (Table 6.1).  Lame symptom, catheter problem, and incision swollen in the 
piglets were the three major problems we met in the study. 
   
The lame symptom was developed in 15 piglets.  The diagnosis of arthritis 
in these piglets was made from the necropsy reports from piglet 22 and piglet 23.  
To prevent the arthritis and incision swollen, several techniques were applied: 
1. Antibiotics (Excenel, 3mg·kg-1·day, intramuscular) (Pharmacia Animal Health, 
Missasaga, Ontario) was used daily from the reception date to the end of the 
study. 
2. Op-site Incise Drape (a plastic drape adhere to the patient over the area of the 
body where the operation will take place) (Smith&Nephew, St. Laurent, Quebec, 
Canada) was used on the surgery skin area during the operation to prevent 
infection. 
3. Bactroban oinment (Glaxo Smithkline, Missasaga, Ontario, Canada) was applied 
to the incisions daily until the incision was healed without complication. 
 
It was a challenge to keep the catheter in the growing piglets for three weeks.  
Catheter problems including the obstruction of catheter and out of vein (because of 
piglets’ scratching) were seen in 14 piglets.  To reduce the catheter problem, the 
following techniques were used: 
1. The patency of catheter was maintained by flushing saline twice a day.   
2. The use of swabable IV connector (CL2000 connector, ICU Medical Inc., San 
Clemente, USA) on the end of the catheter reduced the chances of plugged 
catheter.   
3. A special jacket (fix and protect the catheter on the piglet’s back) was developed 
to protect the catheter. 
4. Frequent visits (every 2 to 3 hours during the day) to check on the piglets were 
crucial to finding the problem early. 
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Table 6.3  Several problems in the piglets during the experiment 
Animal Valid 
1
LameIncision Catheter Comments 
Control      
11 √   X5  
12   X X Euthanized on day 7 
14 √     
16 √     
21 √ X3    
23  X  X Euthanized on day 8 and sent for 
25 √ X3  X5  
Subtotal n=5 n=3 n=1 n=4  
Low Al      
12    X  
22      
32    X  
42      
52  X X X  
62    X  
7 √ X3  X5  
8 √ X3  X5  
9 √     
10 √     
13  X   Euthanized on day 14 
17  X   Euthanized on day 7 
20 √     
22  X  X Euthanized on day 14 and sent for 
24 √     
26 √ X3    
Subtotal n=7 n=7 n=1 n=7  
High Al      
15  X  X Euthanized on day 17 
18 √ X3    
19 √     
27 √     
28 √     
29 √   X5  
30 √ X3    
Subtotal n=6 n=3 n=0 n=2  
PN      
31 √ X3   Euthanized on day 14 
32 √  X4 X5 Euthanized on day 14 
33 √     
34 √     
35 √     
36 √     
Subtotal n=6 n=1 n=1 n=1  
Total n=24 n=14 n=3 n=14  
1. The valid data means the data used in the piglet study in the experiment part of the thesis. 
2. These piglets were in the pilot study (numbers1-6). 
3. Minor lame symptom and rescovered one or two days later. 
4. Minor incision swollen and resolved one day after. 
5. Minor catheter obstruction, used saline flushed and resolved 
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Appendix F 
 
Results from the individual piglets 
 
This appendix lists the results of total bilirubin, serum aluminum 
concentration, liver aluminum concentration, urine aluminum concentration, and bile 
aluminum concentration from all 24 individual piglets in the experimental study.  
The concentration of aluminum was determined at Saskatchewan Research Council 
(SRC), Saskatoon by Inductively Coupled Plasma Atomic Emission Spectroscopy 
(ICP-AES).  For the piglets (number 7, 8, 9, 10, 11, 14, 16, 18, 19, 20, 21, 24), the 
detectable limit of aluminum is 30 μg·L-1 (method: ICP-AES, instrument model: 
TJA-ICAP-61E).  For the piglets (number 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 
36), the detectable limit of aluminum is 2.5 μg·L-1 (method: ICP-AES, instrument 
model: G3152A).  For statistical purposes, when the aluminum level was below the 
detectable limit, half of the value was used in the table.   
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Table 6.4  Results from the individual piglets in the control group in the experimental study 
 
Total bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Piglet 
number Day 0 Day 7 Day 14 Day 21 Day 0 Day 7 Day 14 Day 21 
Liver 
aluminum 
(μg·g-1) 
Urine 
aluminum 
(μg·L-1) 
Bile 
aluminum 
(μg·L-1) 
11 2 1 1 1 45 151 151 151 0.08 151 151 
14 1 2 2 2 90 151 151 90 0.14 151 151 
16 1 3 3 1 63 151 151 44 0.01 30 151 
21 0 1 3 3 151 151 100 15 0.01 151 151 
25 1 2 2 1 15 39 22 24 0.02 20 20 
1. The aluminum concentration < 30 μg·L-1, half of 30 μg·L-1 (15 μg·L-1) was used in the table. 
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Table 6.5  Results from the individual piglets in the Low Al group in the experimental study 
 
Total bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Piglet 
number Day 0 Day 7 Day 14 Day 21 Day 0 Day 7 Day 14 Day 21 
Liver 
aluminum 
(μg·g-1) 
Urine 
aluminum 
(μg·L-1) 
Bile 
aluminum 
(μg·L-1) 
7 2 9 2 2 151 151 151 151 1.40 151 65 
8 2 3 6 8 50 151 151 151 0.48 151 150 
9 2 2 2 2 160 780 260 90 0.33 151 151 
10 2 2 2 4 151 110 150 60 0.27 190 60 
20 0 1 2 1 40 151 80 50 0.52 151 151 
24 1 2 3 2 60 630 230 230 1.48 110 80 
26 3 3 2 2 30 110 130 90 1.60 230 60 
1. The aluminum concentration < 30 μg·L-1, half of 30 μg·L-1 (15 μg·L-1) was used in the table. 
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Table 6.6  Results from the individual piglets in the High Al group in the experimental study 
 
Total bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Piglet 
number Day 0 Day 7 Day 14 Day 21 Day 0 Day 7 Day 14 Day 21 
Liver 
aluminum 
(μg·g-1) 
Urine 
aluminum 
(μg·L-1) 
Bile 
aluminum2 
(μg·L-1) 
18 1 3 6 2 151 480 270 270 28 3840 151 
19 3 2 8 2 151 820 320 600 17 1100 90 
27 1 8 5 2 39 1230 578 630 100 477 130 
28 1 14 5 10 50 1300 1320 300 94 1520 250 
29 1 5 7 3 30 1800 2050 2420 100 1460 960 
30 1 3 10 15 10 1490 1680 1060 89 729  
1. The aluminum concentration < 30 μg·L-1, half of 30 μg·L-1 (15 μg·L-1) was used in the table. 
2. There was no bile that could be obtained from piglet 30 at the end of the study. 
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Table 6.7  Results from the individual piglets in the PN group in the experimental study 
 
Total bilirubin (μmol·L-1) Serum aluminum (μg·L-1) Piglet 
number Day 0 Day 7 Day 14 Day 212 Day 0 Day 7 Day 14 Day 212 
Liver 
aluminum 
(μg·g-1) 
Urine 
aluminum 
(μg·L-1) 
Bile 
aluminum3 
(μg·L-1) 
31 2 3 47  9 30 28  0.78 126 5 
32 1 7 21  18 27 30  0.52 269 20 
33 3 48 122 177 14 40 54 70 1.50 144  
34 2 14 74 131 16 114 57 30 1.07 232  
35 2 6 26 86 11 33 66 24 0.73 646  
36 2 3 87 44 16 25 35 24 0.80 136 25 
1. Piglet 31 and piglet 32 were on PN therapy for 14 days. 
2. There were no bile for piglet 33, 34, and 35 at the end of the study. 
 
 
 
